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ABSTRACT 
 
 
Leishmania amazonensis is an intracellular protozoal parasite that causes 
cutaneous leishmaniasis in humans and other mammalian hosts. This disease affects 
people within tropical and subtropical countries. Generally a Th1 cell-mediated host 
immune response is thought to be important for the clearance of the parasite. However, 
throughout this work we have shown that a productive B cell response is important for 
the clearance of the parasite through the production of IgG2a isotype antibodies. These 
antibodies can form small soluble immune complexes that can stimulate the FcγR 
leading to the production of superoxide. Superoxide and nitric oxide are required to kill 
intracellular L. amazonenesis parasites. Our studies have also shown that macrophages 
can be activated to produce these required immune factors if they are stimulated with 
soluble immune complexes, IFN-γ, and Leishmania antigen (tripartite activation). We 
have also found that these three factors can lead to the upregulation of the autophagy 
pathway for the clearance of the parasite. These soluble immune complexes can be 
replaced by novel recombinant proteins that have similar morphology to murine IgG2a 
Fc. These Fc constructs have the ability to recapitulate killing of the parasite and 
superoxide production seen with tripartite activation. All of these factors are important 
for the development of a possible immunomodulating therapy that could be used to treat 
patients infected with this chronic, debilitating disease. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Leishmaniasis – Introduction, History, Epidemiology: 
Leishmaniasis is a vector-borne disease caused by protozoan parasites of the 
Leishmania genus (Kinetoplastida: Trypanosomatidae). Leishmaniasis has been 
present in the human population as far back as humans were able to document 
its presence. Leishmania mitochondrial DNA has been isolated from mummies 
from Egypt and Sudan as early as 1500 BC and from America as early as 800 
BC, before the arrival of Europeans in America.1 In 1903, Leishmania was 
named after Dr. William Boog Leishman found characteristic bodies in the spleen 
of infected patients.2 Leishmaniasis also has several other names including: 
leishmanasis, leishmaniose, Oriental boils, Baghdad Boil, kala azar, black fever, 
sand fly disease, Dum-Dum fever, or espundia.3  
There are 30 different Leishmania species, approximately 20 of which 
have the potential to infect humans. Human infections are zoonotic; the result of 
a recent host transfer from a zoonotic source; or as occurs in urban areas, are 
anthroponotic. These protozoan parasites are transferred to the human by the 
bite of infected female phlebotomine sand flies.4 There are three main forms of 
the disease, including cutaneous, visceral, and mucocutaneous. These different 
forms of disease are caused by different Leishmania species.  
Leishmania species are divided into Old World and New World regarding 
their geographic location. The Old World (Eastern hemisphere) leishmaniasis 
include L. donovani, L. infantum, and L. major. The New World (Western 
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hemisphere) leishmaniases include L. chagasi (L. infantum), L. braziliensis and 
L. amazonensis.  
Leishmaniasis occurs in more than 90 countries in the tropics, subtropics, 
and southern Europe.5 There are approximately 310 million people at risk of 
infection with approximately 1 million cases of cutaneous leishmaniasis reported 
in the last five years and 300,000 cases of visceral leishmaniasis with more than 
20,000 deaths annually.4 Over 90% of visceral leishmaniases occur in six 
countries, including Bangladesh, Brazil, Ethiopia, India, South Sudan, and 
Sudan.  Most cases of cutaneous leishmaniasis occur in Afghanistan, Algeria, 
Brazil, Columbia, the Islamic Republic of Iran, Pakistan, Peru, Saudi Arabia, and 
the Syrian Arab Republic.  
Transmission 
Leishmaniasis is currently classified as a neglected tropical disease. Leishmania 
sp. are mainly transmitted by phlebotomine sand fly vectors between humans 
and other mammalian hosts, making transmission of the disease very difficult to 
control. Rarely within urban areas there is anthroponotic transmission of 
cutaneous and visceral leishmaniasis.  
L. amazonensis causes cutaneous leishmaniasis in the New World. 
Although it is not considered a frequent cause of New World cutaneous 
leishmaniasis, less than 3% of cases, it is a unique species that can lead to 
severe disease with an outcome of diffuse cutaneous leishmaniasis. Leishmania 
amazonensis is transmitted by sand flies that take a bloodmeal from an infected 
host and inject the infective metacyclic promastigotes into the skin of a human or 
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other mammal. The promastigotes then transform into amastigotes and multiply 
inside macrophages where another sand fly can later take up the infected cells, 
which transform from amastigotes to promastigotes within the midgut of the sand 
fly.5 (Figure 1) 
 
 
Figure 1. Life cycle of Leishmania, www.cdc.gov, accessed October 20, 2015. 
Leishmaniasis is transmitted by the bite of a sand fly. The sand fly takes a blood 
meal and injects the promastigote into the bloodstream. The promastigote is 
taken up by macrophages and transforms into amastigotes. Amastigotes 
replicate and reside within macrophages where they can be taken up by sand 
flies when they take a blood meal. In sand flies, amastigotes transform back to 
promastigotes within the sand fly hindgut. 
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Disease, Diagnosis, Treatment, Prognosis 
There are three main diseases in humans including: visceral leishmaniasis (VL), 
cutaneous leishmaniasis (CL), and mucocutaneous leishmaniasis. These three 
different forms of disease are caused by different species of Leishmania and the 
different host response to the parasite.  
Visceral leishmaniasis is the most severe form of disease. It is caused by 
L. donovani and L. infantum. The clinical symptoms associated with VL include 
fever, anemia, splenomegaly, hepatomegaly, and progressive cachexia. This 
disease occurs most frequently in immunosuppressed individuals, such as HIV 
infected patients. Other symptoms can include lymphadenopathy and persistent 
diarrhea. The prognosis of this disease is varied and spontaneous recovery can 
occur; although, full-blown disease (untreated) is fatal.6  
Cutaneous leishmaniasis is caused by L. major (Old World) or L. 
amazonensis and L. braziliensis (New World), along with many other species. 
The lesion associated with CL typically first appears as a persistent insect bite 
that gradually enlarges. The lesion can then become an open sore. Spontaneous 
resolution generally occurs, however the time for resolution varies depending on 
the species of the parasite and host response.6 Diffuse cutaneous leishmaniasis 
(DCL) is a manifestation of cutaneous leishmaniasis in which lesions may be 
restricted or widespread over the body and can be caused by L. amazonensis. 
DCL is generally restricted to Venezuela and the Dominican Republic in the 
western hemisphere. DCL occurs due to the lack of an effective host immune 
response and there are typically numerous parasites within lesions. 6   
  
5
Mucocutaneous leishmaniasis occasionally occurs and is caused by L. 
braziliensis (New World). Mucocutaneous leishmaniasis occurs at or close to a 
mucosal surface after the bite of a sand fly. Classic mucocutaneous 
leishmaniasis occurs following the resolution of a cutaneous lesion. The clinical 
symptoms associated with this disease include destruction of mucosa and 
associated cartilage and the disfiguration of the face or affected surface.6  
Diagnosis of leishmaniasis can be difficult to achieve. It occurs mainly by 
clinical exam in endemic areas; however confirmation of the disease diagnosis 
can be established through the demonstration of amastigotes in infected tissues. 
This can be achieved by fine needle aspirates or tissue biopsies of bone marrow 
and spleen. Other assays have been developed for the diagnosis of 
leishmaniasis, including serology and PCR. Serologic assays are most 
commonly used for diagnosing visceral leishmaniasis and these assays include 
antigen-based direct agglutination tests and commercially available 
immunochromatographic dipstick tests. These tests have high sensitivity and 
specificity.7 Another assay that is occasionally used for the diagnosis of 
cutaneous leishmaniasis is the Montenegro skin test (MST). This test has high 
sensitivity and specificity, however it does not distinguish between past and 
present infections.7 PCR can also be used for the detection of Leishmania 
nucleic acids and allows for a very specific and sensitive result. This method can 
be used for the quantification of parasite load following treatment or to identify 
the Leishmania species causing the infection.7 In a clinical setting a combination 
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of these different diagnostic assays would be used to help confirm a diagnosis of 
leishmaniasis.  
There is currently no vaccine available for human leishmaniasis. Visceral 
leishmaniasis can be difficult to treat and is often fatal in full-blown infections. 
The traditional treatment of VL has been the use of pentavalent antimonials, 
however other treatments have also been developed. These treatments include 
amphotericin B, Paromomycin, and miltefosine. These drugs have both 
advantages and disadvantages, and none of them are 100% effective in parasite 
clearance. Several drugs have been implicated for oral treatment; some 
examples include allopurinol, azole drugs and miltefosine. The allopurinol and 
azole drugs have little evidence or scientific research to show clinical efficacy, 
therefore their use is not recommended.8 Miltefosine is another oral drug that has 
demonstrated good clinical efficacy of cure rates at approximately 85%. 
However, relapse 12 months following miltefosine treatment can be as high as 
20%. 
Parenteral treatments for leishmaniasis are also available and these 
include pentavalent antimonials, Amphotericin B deoxycholate, liposomal 
Amphoteracin B, Pentamidine, and Paromomycin. Pentavalent antimonials were 
considered the first line of treatment and have been used since the late 1940s 
although parasite resistance has development in certain geographic areas. 
Parasite resistance is particularly established in India where resistance rates are 
as high as 60%.8 Cure rates with pentavalent antimonials range from 80-100%. 
Cardiac toxicity with pentavalent antimonials can reach as high as 17% if 
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treatment regimens extend longer than 28 days.8 Amphotericin B deoxycholate 
and liposomal Amphotericin B are other first line drugs against leishmaniasis. 
These drugs are very effective and can have cure rates ranging from 95-100%, 
with little toxicity. Paromomycin is not recommended as a sole therapy against 
VL as cure rates were as low as <50% in one study.8  
These drugs have high rates of toxicity and variable efficacy. All of these 
treatments can have different beneficial aspects that allow for their preferential 
selection or a combination of different treatments within patients. Other factors 
also need to be considered when treating a patient, such as the development of 
parasite drug resistance, HIV-Leishmania co-infection, malnourishment, or other 
co-infections. 
Many cases of cutaneous leishmaniasis will spontaneously resolve 
regardless of the treatment. Cutaneous and mucocutaneous leishmaniasis 
treatments are often poorly justified and have limited effectiveness. Nevertheless, 
many treatment options are available including physical therapies, topical drug 
therapies, oral drug therapies, and parenteral drug therapies. The treatment 
chosen for patients with cutaneous and mucocutaneous leishmaniasis greatly 
depends on the species of Leishmania responsible for disease. Old World 
leishmaniases are more likely to spontaneously resolve than New World 
leishmaniases or mucocutaneous disease. These facts lead most physicians to 
treat Old World cutaneous lesions with physical therapies such as 
thermotherapy, cryotherapy, or CO2 laser treatment. For New World cutaneous 
leishmaniasis the preferred treatment is systemic therapy, however this includes 
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risky side effects and long treatment periods. In the case of cutaneous 
leishmaniasis caused by L. amazonensis and mucocutaneous leishmaniasis, 
pentavalent antimonials seem to be the best treatment option.9  
 More research is needed to develop better treatment options with less 
severe side effects and better efficacy. These treatments should also lead to 
quicker lesion resolution and prevent disfiguration. 
Murine cutaneous Leishmaniasis 
The mouse model is a very important tool for the study of the host immune 
response to Leishmania parasites. Both L. major and L. amazonensis cause 
cutaneous leishmaniasis in mice after experimental infection. Genetically 
susceptible and resistant strains of mice have been pivotal in understanding the 
immunopathogenesis of leishmaniasis. Depending on the mouse strain and the 
species of Leishmania some animals develop a lesion that heals after a variable 
amount of time while others may develop progressive lesions that eventually lead 
to the death of the animal.10 BALB/c mice develop uncontrolled disease when 
infected with either L. major or L. amazonensis and other mouse strains show 
various levels of susceptibility to these pathogens. C3H mice are able to heal 
infection with L. major but develop chronic disease when infected with L. 
amazonesis. C57BL/6 and C57BL/10 mice also heal L. major infections but 
develop chronic lesions that can metastasize when infected with L. 
amazonensis.10 The genetic predisposition for susceptibility to L. major infection 
in mice is determined by their dominance of a Th1 or Th2 phenotype driven by 
IFN-γ and IL-12 or IL-4 respectively.11 
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C3H mice that are coinfected with L. major and L. amazonensis or prior 
infection with L. major can confer protection against L. amazonesis.12 The 
outcome of the host immune response to Leishmania spp. are dependent upon 
the host immune response, nutritional status, and parasite species or strain.13 
Infection of mice with Leishmania major can lead to cutaneous leishmaniasis and 
healing of that infection requires the production of Th1 cytokines, the activation of 
macrophages, and the production of reactive oxygen species and reactive 
nitrogen intermediates, such as nitric oxide.14, 15 Alternatively, infection of mouse 
models with L. amazonensis can lead to non-healing cutaneous leishmaniasis, 
as these parasites are highly resistant to many neutrophil and macrophage 
derived leishmanicidial effector molecules.14, 15 The Leishmania immunology 
paradigm has been well described using the BALB/c mouse model and L. major 
infection. However, there are many complexities in the mechanisms responsible 
for immunity against these pathogens, along with significant species variation, 
therefore research is ongoing. 
 L. amazonensis is more difficult to eliminate and causes chronic infections 
in comparison to L. major. Our lab has shown that an impaired immune response 
to L. amazonensis may be a result of an impaired ability of immune cells to 
transition from a naïve to an effector phenotype. L. amazonensis infected 
dendritic cells have altered expression of surface markers, cytokine production, 
maturation, and function. These include significantly reduced CD40 surface 
expression and a decreased number of IL-12p40 producing cells within the 
draining lymph node of L. amazonensis infected mice.16 CD40L-/- are more 
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susceptible to L. amazonensis infection, suggesting the CD40-CD40L 
interactions are important for the generation of a host cellular immune 
response.17 Lipophosphoglycan (LPG) a glycolipid on the surface of Leishmania 
has been shown to activate extracellular signal-regulated kinases (ERKs), c-Jun 
N-terminal kinase (JNK), and the p38 MAP kinase, and both p38 and ERK 
appear necessary to induce IL-12 and nitric oxide production. Inhibiting the 
phosphorylation of ERK in vitro can result in recovering the DC phenotype 
resulting in an increase in IL-12 production.16 Some other parasite virulence 
factors include the modulation of TLR signaling, IFN-γR downregulation, and the 
induction of IL-10.18 All of these responses skew the host immune response to 
favor parasite survival. LPG on L. amazonensis can also affect host cell kinases 
and phosphatases. LPG can interfere with the binding of regulators such as Ca2+ 
and can block protein kinase C (PKC) membrane insertion and activation.19 The 
blockage of PKC can have a critical role in preventing superoxide production 
through the downstream effects of nicotinamide adenine dinucleotide phosphate 
(NADPH) complex assembly.19 There are multiple virulence factors that 
Leishmania uses to prevent a protective host immune response and to favor the 
intracellular survival and replication of amastigotes. As these parasite induced 
virulence factors are elucidated, the modulation of these specific signaling 
pathways may be effective in immunomodulatory treatments. This has the 
potential to lead to a decrease in intracellular parasite survival and replication. 
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The role of B cells in Leishmaniasis 
B cells are generally not given much attention in Leishmania infections, as the 
focus remains on the generation of a productive Th1 response with IFN-γ and IL-
12 for lesion resolution. However, our lab has shown that B cells may be playing 
a larger role in the host’s immune response to Leishmania than previously 
thought. Our lab has demonstrated that CD4+ T cells and B cells can limit L. 
amazonensis survival in macrophages in vitro, and this correlates with 
susceptibility to L. amazonensis infection by C57BL/6 mice, which have a 
deficiency in their B cell response.20, 21  
B cells develop from a single precursor bone marrow stem cell line and 
mature into many mature B-cell subsets, including memory B cells and plasma 
cells. B cell subpopulations are distinguished by their receptors and cell surface 
markers of activation or differentiation. The different B cell subsets include pro-B 
cells, pre-B cells, immature and transitional B cells, plasmablasts, and plasma 
cells.22  
B cells can be found throughout the body in a number of organs in a 
normal individual. These include in the bone marrow (precursors, plasma cells), 
blood (transitional, naïve mature, and memory B cells, plasmablasts, plasma 
cells), secondary lymphoid tissues (mature naïve, memory B cells). B cells 
subpopulations display many similar cell surface markers although some differ 
amongst populations. One example is the presence of CD27 as a marker of 
memory B cell populations. CD20 antigen is expressed on a majority of B cells, 
but not stem cells, pro-B cells, or terminally differentiated plasma cells.22 CD20 
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antigen is a transmembrane protein that is thought to be involved in the activation 
and proliferation of B cells. 
Described disorders of the B cell lineage mainly consist of neoplastic or 
autoimmune disorders. B cell lymphomas occur in humans and animals and 
consist mainly of follicular lymphoma, non-Hodgkin’s lymphoma, and chronic 
lymphocytic leukemia.22 Numerous autoimmune disorders are described 
throughout the literature. These diseases can occur through the production of 
autoantibodies by B cells or plasma cells. Some examples include rheumatoid 
arthritis, granulomatosis with polyangitis (GPA), and microscopic polyangitis 
(MPA). The use of antibodies against B cells was developed in the late 1980s 
and 1990s, where an antibody is used to deplete the specific cell type by 
antibody dependent cell-mediated cytotoxicity. Rituximab, an anti-CD20 
monoclonal antibody (Rituxan ©, Genentech, Biogen, IDEC) was first licensed for 
use in 1997 against follicular lymphoma and is now licensed for use against Non-
Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid 
Arthritis (RA), Granulomatosis with Polyangitis (GPA) (Wegener’s 
Granulomatosis), and Microscopic Polyangitis (MPA). Since that time other anti-
CD20 antibodies have been developed for use and include Ofatumumab, 
Ocrelizumab, Veltuzumab, AME-133v, PRO131921, or GA101.23  
 Anti-CD20 therapy has been successful in the depletion of B cells in 
humans and mice with very few reported side effects. Different subpopulations of 
B cells along with the location of the B cell population yield different responses to 
the anti-CD20 therapy. B cells within the peripheral blood are most susceptible to 
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anti-CD20 depletion therapy and many studies report a depletion efficiency of 
99% or higher.22 Populations that are more resistant to therapy include peritoneal 
B1-type B cells, germinal center B cells, and marginal zone B cells.22, 24 These 
differing sensitivities may be due to the inefficiency of effector cells at getting to 
these locations or to a defect in antibody-dependent cellular cytotoxicity. For 
example, the FcR is important in B cell depletion and polymorphisms of this 
receptor can effect the efficiency of anti-CD20 therapy.25 Some suggest that 
higher doses of antibodies are needed to deplete B cell populations in bone 
marrow, spleen, and lymph nodes in successive order.22 Depletion of solid 
organs is often not complete.  
 Despite relatively high depletion of B cells following anti-CD20 therapy 
there are relatively few studies demonstrating an increased susceptibility to 
infections. Patients receiving rituximab therapy will be immunosuppressed and 
may be more susceptible to chronic infections such as leishmaniasis. Many 
clinical trials have conflicting results regarding the association of anti-CD20 
therapy and infections. One study has shown an increased incidence of 
infections of patients with lymphoma and rheumatoid arthritis receiving 
rituximab.26 A review of recent data showed that rituximab therapy significantly 
increased the risk of infection in patients with lymphoma or other hematological 
malignancies; however, this increased risk of infection was comparable to other 
concurrent treatments in patients with rheumatoid arthritis.27 Patients receiving 
rituximab therapy will be immunosuppressed and may be more susceptible to 
chronic infections such as leishmaniasis. 
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 Patients receiving B cell depletion therapy will repopulate their B cells 
within 6 to 9 months following therapy. This is through the production of naïve B 
cells from the bone marrow stem cells, which then repopulate the peripheral 
blood and secondary lymphoid organs. Plasma cells are often long lived and are 
not affected by anti-CD20 therapy, however the production of new plasmablasts 
and plasma cells will be delayed.  
  
Macrophages 
Macrophages are important immune cells derived from bone marrow monocytes 
that are integral in bridging innate and acquired immune responses. 
Macrophages are phagocytic cells that can travel to the lymph node and present 
antigen to T cells. Macrophages have numerous receptors that allow them to 
phagocytize foreign antigens. The receptors that are reported to play a role in the 
uptake of Leishmania include the third complement receptor (CR3), first 
complement receptor (CR1), mannose receptor (MR), Fc gamma receptors 
(FcγRs, in particular FcγRII), and fibronectin receptors (FnRs).28 
Macrophages have many roles as a part of the innate immune system. 
These roles include recognition and phagocytosis of foreign antigens along with 
different mechanisms employed to ingest those foreign substances. Some ways 
that macrophages kill phagocytized microorganisms include through the acidic 
environment of the lysosome, production of nitric oxide, and superoxide. 
Macrophages follow two main phenotypes, M1 and M2. M1 macrophages are 
characterized by the production of reactive oxygen and nitrogen species, 
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whereas M2 macrophages are characterized by their anti-inflammatory and 
wound repair properties. For the extent of this review we will focus on M1 
macrophage phenotype.29 These macrophages are stimulated by IFN-γ and play 
an important role in innate immunity.  
It is generally accepted that a protective immune response against 
Leishmania is dependent upon the induction of a CD4+ Th1 response.30 CD4+ 
Th1 T cells produce IFN-γ that activates macrophages to kill intracellular 
parasites. IFN-γ induces macrophages to synthesize nitric oxide as well as 
superoxide. Nitric oxide has been shown to play an important role in antimicrobial 
functions and has been shown to be a critical molecule in the parasitical function 
against Leishmania major 31 and has been shown to limit growth of Leishmania 
within infected macrophages.30 Nitric oxide is generated from L-arginine by the 
enzyme NO synthase (NOS).32 There are three forms of NOS, including 
inducible, neuronal, and endothelial. Inducible NOS (iNOS) is induced by the 
presence of cytokines activating neutrophils, macrophages, and other white 
blood cells.33  
The production of reactive oxygen species has also been shown to play 
an important role in the clearance of Leishmania amazonensis.30 The production 
of ROIs is initiated by NADPH oxidase. NADPH oxidase is activated when the 
cytosolic proteins (gp40phox, gp47phox, gp67phox, and Rac2) translocate to and 
interact with the membrane bound proteins (gp91phox, gp22phox, Rap1a) to 
make the active NADPH oxidase. NADPH oxidase produces superoxide, which is 
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used to control intracellular microbes.34 NADPH oxidase can be activated by IFN-
γ, IL-8, or by IgG binding to Fc-receptors or microbial products (such as LPS).34 
Leishmania exhibits many virulence factors that allow it to modulate the 
host immune response in order to ensure its survival. These include modulating 
receptor responsiveness in macrophages and altering host cell kinases and 
phosphatases. Some receptors on the surface of the macrophage that are 
affected by Leishmania include CD40, TLRs, IFN-γ, and IL-10 receptors. Several 
studies have shown that Leishmania-infected macrophages have MAPKs that 
are repressed, causing a decrease in IL-12 and iNOS2 production.35 Parasite 
LPG has been implicated in the inactivation of MAPKs.35 Our lab has also shown 
that L. amazonensis amastigotes inhibited the ability of DCs to undergo proper 
maturation.16 TLRs are thought to be modulated by Leishmania either through 
the suppression of TLR 2, 4, 9, or the adaptor protein MyD88. TLR 4 deficient 
mice had impaired resistance to L. major and TLR9 signaling is suppressed by L. 
major infection. The modulation of TLRs or other pattern recognition receptors 
would lead to a decrease in the cytokines (such as IL-12) produced along with a 
decrease in the induction of iNOS expression.35 Leishmania can also inhibit IFN-
γ receptor signaling through the inhibition of the JAK2/STAT1 pathway. The 
suppression of IFN-γ receptor pathways leads to a decrease in nitric oxide 
production and a decrease in MHC class II expression. Finally, host IgG present 
on the surface of Leishmania amastigotes can interact with the FcγR on the 
surface of the macrophage leading to the induction of IL-10, a potent 
immunosuppressant.19  
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Leishmania LPG has been shown to inhibit protein kinase C activation and 
subsequent intracellular signaling. Leishmania also activate phosphoinositide-3-
kinase (PI3K) signaling, which has been shown to negatively regulate IL-12 
production. In conclusion, there are many ways that Leishmania has evolved to 
use the host cell molecules to its advantage to allow for its intracellular survival. 
 
Fcγ Receptors 
Antibody Fc (Fragment crystallizable) receptors, found on many cell surfaces, 
that mediates binding of immunoglobulin, can induce a variety of immune 
functions by regulating intracellular signaling. Antibody Fc receptors (FcR) are 
named by their ability to bind specific immunoglobulin subtypes. FcγRI (CD64) 
resides on the surface of monocytes and macrophages, and binds the Fc portion 
of IgG1 or IgG2a in humans or mice, respectively, with high affinity. The main 
immune functions of Fc receptor engagement are facilitation of phagocytosis, 
antibody-dependent cell-mediated cytotoxicity (ADCC), induction of the release 
of inflammatory mediators, and the regulation of lymphocyte proliferation and 
differentiation.36 Given their wide array of functions in modulating the immune 
response, new and promising strategies are unfolding for developing molecules 
that are able to mimic the FcR-Ig interaction to exploit immunoregulation.37  
Cell surface expression of FcγRI can be induced by IFNγ. FcγRI can bind 
monomeric IgG and take it up via endocytosis, however this generally leads to a 
recycling pathway unless the receptor is cross-linked with multivalent IgG 
complexes.38 Cross-linked receptors lead to internalization of the antigen-
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antibody complex and activation of the cell to produce effector functions, such as 
superoxide production.39 Phagocytosis of the antigen-antibody complex by 
macrophages results in a pro-inflammatory response and the production of 
superoxide within the phagosome.40 However, the size of the immune complex 
(IC) binding FcγRI affects the signaling pathway that ensues.40 FcγRI signals 
through a common γ chain and activates the proto-oncogene tyrosine-protein 
kinase (SRC) family of kinases, spleen tyrosine kinase (SYK), and has been 
shown to induce superoxide production when bound by large insoluble IC.41 
However, when small soluble ICs bind the FcγRI they are internalized by 
endocytic pathways, leading to other functions, such as receptor expression, 
regulation of signal transduction, antigen presentation, and recycling of those 
receptors.42 Other studies have shown that these small soluble ICs can also 
induce superoxide production upon cross-linking of the FcγRI.43, 44 Further work 
is needed to elucidate how clustering of this single receptor can lead to different 
immune functions at the molecular level. The ability to manipulate these 
receptors in order to get a timely and localized release of inflammatory mediators 
can be helpful in inducing an effective immune response against intracellular 
pathogens.43, 44  
 
Autophagy 
Autophagy is an intracellular homeostatic mechanism important for the 
degradation of cytosolic components that range in size from single proteins to 
entire organelles via autodigestion through the lysosomal pathway. Multiple 
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autophagic pathways exist in mammalian species. Autophagy plays a role in cell 
survival throughout health and disease including, aging, cancer, 
neurodegenerative diseases, immunity, infectious diseases, and chronic 
inflammatory conditions.45  
The process of canonical macroautophagy can be broken down into four 
discrete steps: induction, formation of the autophagosome, autophagosome 
docking and fusion with the lysosome or vacuole, and autophagic body 
breakdown.46 Canonical autophagy can be induced through nutrient deprivation 
or the inhibition of the phosphorylation of mTOR (mammalian target of 
rapamycin), such as occurs with Rapamycin.46 The initiation of autophagy is 
dependent on the ULK1 complex. Next, a double membrane vesicle begins to 
form in the cytosol, resulting in the sequestration of cytoplasmic components. 
This process is highly regulated under the control of GTPases, class III 
phosphatidylinositol-3-kinases (class III PI3K), and various phosphatases.46 
Fusion of the autophagosome with the lysosome depends on microtubules and 
vacuolar protein sorting (Vps) protein complex which function to ensure efficient 
fusion of the autophagosome with the vacuole.46 Autophagosomes can be 
recognized by their microtubule associated protein 1A/1B light chain protein 3 
(LC3), which is conjugated with phosphotidylethanolamine (PE) to form LC3II. 
LC3II facilitates the formation of the double-membrane autophagosome; which 
fuses with a late endosome or lysosome to form the autolysosome.47 Fusion 
causes the release of the single-membrane bound inner vesicle of the 
autophagosome, into the vacuole lumen and the autophagic body is broken 
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down.46 Xenophagy is another type of canonical autophagy that targets bacteria 
for clearance by autophagy.  
Non-canonical autophagy occurs without the formation of a double 
membrane and can lead to autophagosomal degradation through different 
variations of the autophagy pathway.48 These pathways are triggered by several 
cell surface receptors and can be involved in a form of selective autophagy. One 
pathway is known as LC3-associated phagocytosis (LAP), which links signaling 
during phagocytosis with recruitment of phagocytosis machinery.49 The 
recruitment of LC3II to the phagosome is preceded by class III PI3K activity, 
similar to canonical autophagy.50 LAP focuses on extracellular pathogen 
degradation within a phagosome, whereas canonical autophagy targets bacteria, 
parasites, and viruses (xenophagy) that either disable the phagosome or that 
escape into the cytosol.50 Both non-canonical and canonical autophagy play 
complementary functions in immunity, and are important in modulating 
inflammatory pathways.50 Others have also found that this pathway may occur 
through other pathways that do not involve PI3K, such as diacylglycerol 
dependent PKCδ activation.51 
Autophagy has been shown to play a role in innate immunity and can be 
activated through numerous pattern recognition receptors to participate in the 
elimination of microorganisms. Inflammatory cytokines can also be involved in 
the activation of autophagy. IFN-γ may activate autophagy through the function 
of immunity-related GTPases and through the phosphorylation of beclin 1 by 
death-associated protein kinase 1 (DAPK1).52 The signaling mechanisms that 
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autophagy uses for selective degradation of intracellular microorganisms are 
largely undetermined and more research is needed to elucidate the specific 
signaling pathways. However, it appears that lipid second messengers and 
phosphatidylinositol 3-phophate (PI3P) are required for autophagy.53  
Infection with intracellular Leishmania amazonensis, can be a chronic 
debilitating disease in humans. There are currently no vaccines available and 
treatment modalities are often harsh. A productive antibody response is 
important in clearing an infection with L. amazonensis, in our in vivo and in vitro 
models of disease. Modulation of the host immune response for clearance of the 
intracellular parasites may be a possible host-direct immunotherapy. Activating 
macrophages to produce the necessary immune factors to kill the intracellular 
parasite may be a new treatment option that would allow for clearance of the 
parasite after infection without deleterious side effects. The ability to decrease an 
infection with L. amazonensis requires superoxide production within 
macrophages, which appears to be linked to the autophagy pathway to parasites 
for subsequent killing, similar to other intracellular pathogens.   
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Abstract 
Anti-CD20 depletion therapies targeting B cells are commonly used in malignant 
B cell disease and autoimmune diseases. There are concerns about the ability of 
B cells to respond to infectious diseases acquired either before or after B cell 
depletion. There is evidence that the B cell response to existing or acquired viral 
infections is compromised during treatment, as well as the antibody response to 
vaccination. Our laboratory has an experimental system using co-infection of 
C3H mice with both Leishmania major and Leishmania amazonensis that 
suggests that the B cell response is important to healing infected mice. We 
tested if anti-CD20 treatment would completely restrict the B cell response to 
these intracellular pathogens. Infected mice that received anti-CD20 B cell 
depletion therapy had a significant decrease in CD19+ cells within their lymph 
nodes and spleens. However, splenic B cells were detected in depleted mice and 
an antigen-specific antibody response was produced. These results indicate that 
an antigen-specific B cell response towards intracellular pathogens can be 
generated during anti-CD20 depletion therapy. 
 
Keywords: B cell, CD20, Leishmania, immunohistochemistry 
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Introduction 
CD20 is a B-cell specific antigen that is expressed solely on B cells but not 
on early progenitor B cells. CD20 is present on the B cell from the pre-B cell 
stage until the mature B cell stage and is excluded on plasmablasts and plasma 
cells. CD20 is thought to be involved in B cell activation and differentiation.1, 2 
Antibodies against CD20 were developed in the late 1980s and 1990s for the 
treatment of follicular lymphoma, non-Hodgkin’s lymphoma, and cancers of the 
B-cell lineage.3 Rituximab, an anti-CD20 monoclonal antibody (Rituxan©, 
Genentech, Biogen IDEC), was first licensed for use in 1997 against follicular 
lymphoma and is now licensed for use against Non-Hodgkin’s Lymphoma (NHL), 
Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), 
Granulomatosis with Polyangitis (GPA or Wegener’s Granulomatosis), and 
Microscopic Polyangitis (MPA). Other anti-CD20 mAbs have also been 
developed, including Ofatumumab, Ocrelizumab, Veltuzumab, AME-133v, 
PRO131921, and GA101.3 Anti-CD20 monoclonal antibodies are most commonly 
used in therapies against lymphoma and autoimmune disorders, often in 
combination with other immunosuppressive agents. Infections are among the 
most important causes of morbidity and mortality in patients suffering from 
cancer; however, there is a lack of research on the immunosuppression that anti-
CD20 therapies may provoke and whether these therapies may exacerbate these 
secondary infections.4 
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Although anti-CD20 therapies have a proven efficacy and safety, the 
question remains as to whether these therapies lead to an increased 
susceptibility to numerous infections. Many clinical trials have conflicting results 
regarding the association of anti-CD20 therapy and infections; however, one 
study has shown an increased incidence of infections in patients with lymphomas 
and rheumatoid arthritis receiving rituximab.5 A review of recent data showed that 
rituximab therapy significantly increases the risk of infection in patients with 
lymphoma or other hematological malignancies; however, this increased risk of 
infection was comparable to other treatments used in patients with rheumatoid 
arthritis.6 Often, patients receiving anti-CD20 therapies have other complicating 
factors including other active infections.6 Studies have shown that although anti-
CD20 therapies induce B-cell depletion for 6 to 9 months, their immunoglobulin 
levels do not decrease.7 This phenomenon may be due to the presence of long-
lived plasma cells. Plasma cells can survive for periods greater than 1 year, even 
in the absence of a memory B cell population.8 Therefore, most patients 
receiving B-cell depletion therapy do not have an increase in the number of 
infectious complications.7 Other studies have shown that patients receiving anti-
CD20 therapy have an impaired humoral immune response to a primary antigen 
but not to a recall antigen.7, 9, 10 Although these studies show an impaired 
humoral immune response, many patients receiving anti-CD20 therapy still 
produced a measurable antibody response to vaccination and approximately 
20% of the patients were seroprotected.9 Nothing is known about the antibody 
response towards intracellular pathogens during anti-CD20 treatment. Although it 
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is often thought that humoral immunity is, at best, inconsequential towards 
intracellular pathogens or, at worst, detrimental to immune control of intracellular 
pathogens there is emerging evidence that antibodies can play a role in the 
protective response to infection with intracellular pathogens.11, 12, 13, 14 
Leishmaniasis is a commonly used immunologic model of chronic 
infectious disease. Leishmania species are obligate intracellular protozoan 
parasites transmitted by the bite of a sand fly. L. major and L. amazonensis 
cause cutaneous leishmaniasis in many mammalian species, and L. 
amazonensis can lead to non-healing lesions.15 Leishmaniasis is prevalent in 98 
countries in the tropics and subtropics and is considered a neglected tropical 
disease. Multiple mouse models of leishmaniasis are commonly used to study 
host-pathogen dynamics. C3HeB/FeJ (C3H) mice infected with L. major will 
resolve cutaneous lesions within 8 to 12 weeks whereas the same mouse strain 
infected with L. amazonensis develops non-healing cutaneous lesions. However, 
mice co-infected with L. major and L. amazonensis resolve their lesions. Our lab 
has discovered that CD4+ T cells and CD19+ B cells from L. major-infected C3H 
mice are necessary to kill L. amazonensis within infected macrophages in an in 
vitro assay.12, 16, 17 We wanted to test the ability of anti-CD20 administration to 
prevent a detectable Leishmania-specific B cell response to determine if we 
could use this model in our experimental system. Treatment with monoclonal 
anti-CD20 antibodies have been associated with approximately 99% depletion of 
normal B cells in peripheral blood18. However, we show that C3H mice co-
infected with L. major and L. amazonensis and treated with anti-CD20 mAb still 
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have a B cell response to these intracellular parasites. Although the depleted 
mice had significantly less CD19+ cells in the lymph nodes and spleen they still 
had some germinal center formation and detectable antibodies via 
immunoblotting. In this report we determine the ability of the mouse to mount an 
effective immune response to an intracellular infection during monoclonal anti-
CD20 treatments. 
 
Materials and Methods 
Mice 
C3HeB/FeJ (C3H) mice (8-10 weeks of age) were obtained from an in-house 
breeding colony and maintained in a specific pathogen-free facility. Mice were 
infected with either 5 x 106 stationary phase L. major, 5 x 106 stationary phase L. 
amazonensis or 2.5 x 106 L. major (LM) and 2.5 x 106 L. amazonensis (LA) 
promastigotes in 50 μL of PBS in the left hind footpad. In the first experiment 
there were a total of 25 mice with 5 mice per treatment group: 1) LA infected 
mice 2) LM infected mice 3) LM infected and anti-CD20 treated 4) co-infected, 
and 5) co-infected and anti-CD20 treated. In the second experiment there were 
20 mice total with 5 mice per treatment group: 1) uninfected 2) uninfected and 
anti-CD20 treated 3) co-infected and 4) co-infected and anti-CD20 treated. All 
procedures involving animals were approved by the Institutional Animal Care and 
Use Committee at Iowa State University. Lesion size was monitored and the 
results were expressed as the difference between the footpad thickness for the 
uninfected foot and the footpad thickness for the infected foot. 
  
33
 
B-cell depletion 
Mice were given intravenous injections of 200 μg anti-CD20 mAb (IgG1) provided 
by Biogen IDEC (Cambridge, MA) or 200ug of IgG1 isotype control (BioXcell, 
West Lebanon, NH) two weeks post-infection. Mice were then given 
intraperitoneal injections of anti-CD20 mAb or IgG1 isotype control every 2 
weeks for a total of 3 treatments.19  
 
Parasites and Antigens 
L. amazonensis (MHOM/BR/00/LTB0016) and L. major (MHOM/IL/80/Friedlin) 
promastigotes were grown in complete Grace’s medium (Atlanta Biologicals, 
Lawrencville, GA) to stationary phase, harvested, washed in endotoxin free PBS 
(Cellgro, Herdon, VA) and prepared to a concentration of 1 x 108 parasites/ml. 
Freeze-thawed Leishmania antigen was obtained from stationary phase 
promastigotes as previously described.20  
 
Flow Cytometry 
For flow cytometry analysis of surface molecule expression, 1 x 10
6 total draining 
lymph node cells or splenocytes were washed in 2 ml of fluorescence-activated 
cell sorting buffer (FACS, 0.1% sodium azide and 0.1% bovine serum albumin in 
phosphate buffer saline). Fcγ receptors were blocked with 10% purified rat anti-
mouse CD16/CD32 antibody (BD Pharmingen, San Diego, CA) in 1 mg/ml rat 
IgG for 20 minutes at 4°C to prevent non-specific binding. Cells were then 
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incubated with the appropriate antibody or isotype control for 30 minutes on ice in 
the dark. The antibodies used include phycoerythrin-labeled CD19 and 
phycoerythrin-labeled rat IgG2a isotype control. Antibodies were purchased from 
BD Pharmingen (San Diego, CA). Following staining, cells were washed in 2 ml 
of FACS buffer and fixed in 200 μl of 1% paraformaldehyde and stored at 4°C 
until analysis. Analysis was performed on a BD FACScanto flow cytometer 
(Becton Dickinson, San Jose, CA), and data analyzed using FlowJo software 
(Tree Star, Inc., Ashland, OR). 
 
Lymph node and Spleen Histopathology and Immunohistochemistry 
Spleens and popliteal lymph nodes from the left hind leg draining the site of 
infection were harvested and placed in cassettes in 10% neutral buffered 
formalin for histological and immunohistochemical analyses. Histological 
examination was performed on paraffin-embedded tissues cut at 5-μm thickness 
onto positively charged slides and stained with H&E. For immunohistochemistry, 
slides were de-paraffinized and blocked with 20% normal rabbit serum. The 
sections were then incubated with either a rat anti-mouse B220/CD45R antibody 
(BD Harlingen, San Diego, CA) at a concentration of 1:50 or biotin-labeled PNA 
(Vector Laboratories, Burlingame, CA) at a concentration of 1:100 in 10% normal 
rabbit serum. The slides were rinsed with PBS and then incubated with biotin-
labeled goat anti-rat IgG (KPL, Gaithersburg, MD) at a concentration of 1:500 in 
TBS for the B220/CD45R labeled slides. Slides were washed and incubated with 
peroxidase-conjugated streptavidin (BioGenex, San Ramon, CA) for 15 minutes. 
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After 2 PBS washes, the color was developed with Nova Red (KPL, 
Gaithersburg, MD). The slides were then counterstained with Harris’ hematoxylin, 
then dehydrated and mounted with coverslips.  
 
Immunoblot Analysis 
Protein content of all cell extracts was determined via BCA protein assay (Pierce, 
Rockford, IL) according to manufacturer’s recommendations, and all samples 
were normalized to 2 mg/ml using distilled water. Samples (20 to 30 μg of 
protein) were heated for 4 minutes at 95°C in 4x loading buffer and 
electrophoresis was performed on a 12% SDS-polyacrylamide electrophoresis 
gel. Gels were transferred onto polyvinylidene fluoride membranes, blocked with 
5% dry milk, and probed with pooled serum from mice. Signals were detected 
with horseradish-peroxidase-conjugated goat anti-rabbit antibodies (1:20,000) 
(Jackson ImmunoResearch, West Grove, PA) using the SuperSignal West 
chemiluminescent substrate (Pierce, Rockford, IL) and signal was detected with 
radiography film (Midsci, St. Louis, MO).  
 
Statistics 
Statistical analysis was performed with Prism5 (Graph-Pad Software Inc., La 
Jolla, CA). Differences between groups were determined using unpaired t-tests 
or a Mann-Whitney U-test when appropriate. P values <0.05 were considered 
statistically significant. 
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Results 
C3H mice co-infected with L. major and L. amazonensis resolve cutaneous 
lesions following B cell depletion 
We have previously demonstrated that C3H mice will heal a co-infection with L. 
major and L. amazonensis by 10 to 12 weeks post-infection.11 However, we have 
also shown that a productive B cell response correlates with healing a co-
infection with L. major and L. amazonensis.12 We tested the hypothesis that anti-
CD20 treatment would eliminate a B cell response to infection with these 
intracellular parasites. We infected mice with L. major and L. amazonensis and at 
2 weeks post-infection, began administration of B cell depletion therapies, as 
described above. We observed no significant differences in the kinetics of lesion 
development between co-infected mice that received the anti-CD20 or isotype 
control treatment throughout the time course of the study (Figure 1). In addition, 
lesion development in the co-infected groups was similar to the kinetics of lesion 
development in L. major-infected mice treated with anti-CD20 or isotype control 
antibodies (data not shown). Altogether, these data indicate that B cell depletion 
had no effect on lesion development of either co-infected or L. major-infected 
mice.  
  
37
 
Figure 1. Co-infection of C3HeB/FeJ (C3H) mice with Leishmania major (LM) and 
L. amazonensis (LA) allows for lesion resolution by 10 weeks post-infection 
irrespective of B cell depletion therapy. Mice were inoculated with LA and LM 
stationary phase promastigotes in the left hind footpad. Mice were then treated 
with anti-CD20 or an isotype control at two weeks post infection and every two 
weeks until the end of study. Data are representative of two separate 
experiments. 
 
CD20 depleted C3HeB/FeJ mice have significantly fewer CD19+ cells 
present in draining lymph nodes and spleens 
In order to determine how the anti-CD20 antibody treatment affected B cells, we 
analyzed draining lymph node and spleen cell homogenates at 10 weeks post-
infection by flow cytometry with anti-CD19 to identify B cells. We used anti-CD19 
instead of anti-CD20 or anti-B220 to avoid antibody interference and to allow us 
to differentiate B cells from plasmacytoid dendritic cells, which also express 
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B220.21 CD19, in conjunction with CD21 and CD81, is part of the B cell co-
receptor.22 CD19, like CD20 is present on B cells throughout the developmental 
stages, excluding plasmablasts and plasma cells. 23 At 10 weeks the percentage 
of CD19+ B cells from the draining lymph nodes or spleen of anti-CD20-treated 
mice was significantly less as compared to isotype-treated mice (Figure 2A and 
2B). Overall, the percentage of CD19+ B cells in the spleen and draining lymph 
node of isotype-treated mice were similar, 40% and 50% respectively. However, 
post-treatment, we observed a 97.5% reduction of CD19+ B cells in the draining 
lymph node of anti-CD20 treated mice, but only an 80% reduction in the 
percentage of CD19+ B cells in the spleen of treated mice (Figure 2A and B). 
These data would suggest that anti-CD20 antibody treatment differentially affects 
B cell depletion, with the spleen being less affected by the treatment. Similar 
results were found in L. major infected mice with more depletion in the lymph 
nodes as compared to the spleen (data not shown).  
To further assess the B cell response, we also compared total lymphocyte 
counts from lymph nodes and spleens of co-infected mice with and without anti-
CD20 treatment. Co-infected mice treated with anti-CD20 had significantly less 
lymph node cells and splenocytes compared to the isotype controls (Figure 2C). 
This was also true for L. major-infected mice treated with anti-CD20 (data not 
shown).   
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Figure 2. Mice co-infected with Leishmania major (LM) and L. amazonensis (LA) 
that received anti-CD20 monoclonal antibody therapy had significantly less 
CD19+ cells and significantly fewer total lymphocytes within the draining lymph 
nodes as compared to the isotype control. Total draining lymph node cells and 
splenocytes were harvested at 10 weeks post-infection. Cells were analyzed via 
surface expression of CD19. (A, B, C). Data are the mean +/- SEM of two 
separate experiments. A, B *P<0.0001, C *P=0.0048 (t-test). 
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C3HeB/FeJ mice depleted with anti-CD20 have smaller lymph nodes and 
altered lymph node histomorphology 
Next we characterized the histomorphology of draining lymph nodes and spleens 
from anti-CD20 and isotype control-treated mice 10 weeks post-infection with L. 
major and L. amazonensis. Lymph nodes from co-infected mice had reactive 
lymphoid hyperplasia with a sinus histiocytosis. There was diffuse expansion of 
the cortex due to marked proliferation of lymphocytes within the paracortex, 
follicles, and medullary cords. There was also hypercellularity of the medullary 
sinuses composed of infiltrates of inflammatory cells consisting mainly of 
macrophages with fewer lymphocytes, plasma cells, and neutrophils (Figure 3).  
 Draining lymph nodes from anti-CD20 treated mice were significantly 
smaller as compared to the isotype-treated controls (Figure 3). Anti-CD20 
treatment also resulted in a loss of normal lymph node architecture and a lack of 
follicular organization. There was accentuation of the lymph node stroma, 
including numerous fibroblasts and adipose cells admixed with lymphocytes, 
plasma cells, and fewer neutrophils (Figure 3).  
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Figure 3. Mice co-infected with Leishmania major (LM) and L. amazonensis (LA) 
that received anti-CD20 monoclonal antibody therapy had immunopathology and 
significantly smaller draining lymph nodes. Draining lymph nodes and spleens 
were harvested at 10 weeks post-infection and placed in 10% neutral buffered 
formalin. Histological examination was performed on paraffin-embedded tissues 
cut at 5-μm thickness onto positively charged slides and stained with H&E. Co-
infected mice that did not receive anti-CD20 had a reactive lymphoid hyperplasia 
with a sinus histiocytosis (A). Co-infected mice that received anti-CD20 treatment 
had small lymph nodes with accentuation of the stromal fibroblasts and adipose 
cells (*) (B). The lymph node size was measured using CellSens Standard 1.9 
(Olympus) (C). Data are the mean +/- SEM of two separate experiments. 
*P=0.0003 (t-test).  
 
C3HeB/FeJ mice depleted with anti-CD20 have significantly less 
B220/CD45R positive immunostaining and a significant difference in the 
number of germinal centers in the draining lymph node 
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Anti-B220/CD45R and biotin peanut agglutinin (PNA) immunohistochemistries 
were performed to compare B cell populations and germinal center formation, 
respectively between the B cell depleted and isotype-treated groups of co-
infected mice. Mice that were B cell depleted had significantly less B220/CD45R 
immunostaining as compared to the isotype-treated groups (Figure 4). 
B220/CD45R is predominantly expressed on all B lymphocytes, including pro, 
mature, and activated B cells, and most B220+ cells are also CD19+.  
 
Figure 4. Mice co-infected with Leishmania major (LM) and L. amazonensis (LA) 
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that received anti-CD20 therapy had significantly less immunostaining for 
B220/CD45R. Co-infected mice that did not receive anti-CD20 treatment had 
significantly more B220+ immunostaining in both the draining lymph node (A, C) 
and spleen  (D). Co-infected mice that received anti-CD20 treatment had very 
little positive immunostaining for B220/CD45R (B). Data are representative of two 
separate experiments +/- SEM. *P<0.0001 (t-test). 
 
Biotin peanut agglutinin (PNA) is generally used to identify mature 
lymphocytes in germinal centers. The germinal center score was significantly 
different between the isotype control and anti-CD20 treated draining lymph 
nodes. There were few small PNA positive germinal centers throughout the 
isotype control (Figure 5A), but no germinal centers were seen in the anti-CD20 
treated draining lymph nodes (Figure 5B). However, there were no significant 
differences in the germinal center scores of the spleens between co-infected 
mice that had been treated with anti-CD20 or an isotype-control antibody. There 
were very low numbers of germinal centers in the isotype control spleens at 10 
weeks post-infection, despite finding only one germinal center in an anti-CD20 
treated mouse spleen.  
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Figure 5. Mice co-infected with Leishmania major (LM) and L. amazonensis (LA) 
that received anti-CD20 therapy had a significant decrease in the number of 
germinal centers in the draining lymph nodes but not the spleen. 
Photomicrographs of biotin peanut agglutinin (PNA) staining highlights a germinal 
center (A, inset) within a control mouse compared to negative immunostaining 
within a B-cell depleted lymph node (B, inset). Histological germinal center 
scores for PNA immunoreactivity were performed at 10 weeks post-infection. 
Score is based on the number of PNA+ germinal centers within the tissue section 
of a single draining lymph node. Data are representative of two separate 
experiments +/- SEM. *P=0.0400 (C), P=0.930 (D) (Mann-Whitney U test). 
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C3HeB/FeJ mice treated with anti-CD20 mAb produce a specific antibody 
response 
Based on our data thus far, anti-CD20 treatment resulted in depletion of B cells 
from both the draining lymph node and spleen, with the spleen containing readily 
detectable populations of B cells and a rare germinal center. We hypothesized 
that perhaps, despite the observed B cell depletion, there was still a detectable 
antigen-specific antibody response. In order to test this, we performed an 
immunoblot with serum collected from the co-infected mice treated with anti-
CD20 or isotype control antibody, at 10 weeks post-infection. The immunoblot 
was performed for total IgG, IgG2a, and IgG1. The depleted mice still produced 
L. major and L. amazonensis specific antibodies (Figure 6). 
 
 
Figure 6. Co-infected mice treated with anti-CD20 still produce parasite-specific 
antibodies. Western blot analysis of parasite-specific production of total IgG and 
isotypes IgG1 and IgG2a were performed at 10 weeks post-infection. Freeze-
thawed Leishmania major (LM) and L. amazonensis (LA) antigen were separated 
on a polyacrylamide gel and protein was transferred to a polyvinylidene fluoride 
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(PVDF) membrane. The blots were subsequently hybridized with mouse serum 
(1:25 dilution) pooled from 5 C3H control mice and 5 C3H B-cell depleted mice 
that were co-infected with L. major (LM) and L. amazonensis (LA). Following 
serum hybridization the membranes were probed with goat anti-mouse 
antibodies to total IgG, IgG1, or IgG2a. Results are from one experiment at 10 
weeks post-infection. 
 
Discussion 
The work presented in this manuscript demonstrates that mice co-infected with L. 
major and L. amazonensis followed by treatment with monoclonal anti-CD20 
antibodies resolved cutaneous lesions with normal kinetics (Figure 1). Anti-CD20 
antibody treatment resulted in a 97.5% reduction of CD19+ B cells in draining 
lymph node and an 80% reduction in the spleen compared to isotype controls 
(Figure 2A & B). Anti-CD20 treatment led to significantly less total lymphocytes 
(Figure 2C), significantly smaller lymph nodes (Figure 3), significantly less B220+ 
immunostaining (Figure 4), and significantly fewer germinal centers within 
draining lymph nodes (Figure 5). However, treated mice still had detectable 
antigen-specific antibodies to L. major and L. amazonensis antigens. Given these 
results, we have demonstrated that mice treated with anti-CD20 depletion 
antibodies at 2 weeks post-infection retain a population of responsive B cells and 
are capable of developing a detectable antibody response to the intracellular 
pathogen.  
In this study mice were treated with anti-CD20 antibody therapy at 2 
weeks post-infection to ensure a proper CD4+ T cell response. Other studies 
have shown that B cells regulate the initial proliferation of CD4+ T cells after 
encounter with antigen, influence the maintenance of CD4+ T cells, have roles in 
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CD4+ T cell memory responses, and can influence regulatory T cell numbers and 
function.24, 25, 26 Therefore, we did not begin B cell depletion therapy before 
infection, to ensure the functionality of the effector CD4+ T cell populations that 
are needed to resolve cutaneous leishmaniasis.  
It is possible that the mice were able to mount an effective humoral 
immune response to the Leishmania antigens within the first 2 weeks before 
depletion therapy began. This may have lead to the development of long-lived 
antigen-specific plasma cells that would not be affected by the anti-CD20 
therapy. The anti-CD20 dose we used was comparable to other murine studies 
that demonstrated B cell depletion with some studies depleting essentially all 
splenic B cells.27, 28 Our experimental system resulted in only an 80% reduction 
of B cells in the spleen. In addition, our data differs from some articles that have 
shown that bone marrow and spleen are more easily depleted than lymph 
nodes.1, 28, 29 We expected a more robust depletion and although we did not have 
an opportunity to test it, a reasonable hypothesis is that the decreased efficiency 
in depletion may be because of the ongoing chronic intracellular infection. It 
would be interesting to determine if splenic B cells are relatively resistant to anti-
CD20 depletion during a chronic infection, in contrast to draining lymph node B 
cells which had a 97.5% reduction in B cells. Many factors can influence 
depletion, including the drug dose administered, distribution to tissues, B-cell 
intrinsic and microenvironment factors affecting recruitment of effector 
mechanisms and antigen and effector modulation.1, 29  
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Other possible explanations for the lack of total depletion of functional B 
cells include the presence of CD20+ B cells that are resistant to anti-CD20 
therapies, such as marginal zone B lymphocytes, which have been suggested to 
be resistant to rituximab depletion.30 The site at which the B cells are located 
may also play a large role in the ability of the anti-CD20 depletion therapies. 
These differences by location may be due to the body’s ability to clear antibody 
targeted cells or the lack of FcR+ cells that are able to clear the targeted cells.18  
Another less likely theory that could account for the development of 
antibodies includes the presence of a CD20- or CD20low population of B cells that 
are not depleted by conventional B cell depletion therapies with anti-CD20 
antibodies that are still able to produce an antibody response. This may explain 
the different pattern of immunoglobulins seen on the immunoblots (Figure 6). 
Regardless, our results support other studies that have shown that despite B cell 
depletion therapy patients are still able to mount a humoral immune response to 
a primary antigen, although that response may be impaired.7, 9, 10, 31 In our 
experimental infection we show that mice were able to produce a demonstrable B 
cell response to an intracellular pathogen despite treatment with anti-CD20 
antibodies. These results precluded our ability to definitively test the role of B 
cells during Leishmania co-infection.  
To our knowledge, the work presented here describes, for the first time, 
the parameters of the B cell response to Leishmania infection after anti-CD20 B 
cell depletion. We showed that despite B cell depletion, the infected mouse is still 
able to mount a pathogen-specific humoral immune response. Since B cell 
  
49
depletion therapy is common in people and is often used in conjunction with 
other immunosuppressive therapies, further research is necessary to determine 
the risks of B cell depletion therapy in patients with simultaneous infections and 
the possible differential susceptibility of B cell subpopulations to depletion during 
chronic infection. Therefore, further understanding of this model could better 
reflect some real life scenarios, in which those needing B cell therapy also have 
concurrent infections or established infections prior to treatment.  
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Abstract 
 
The intracellular protozoal parasite Leishmania can cause cutaneous and 
visceral leishmaniasis, a vector borne disease that infects approximately 1 million 
people each year. C3H mice infected with L. amazonensis develop chronic 
cutaneous lesions with large parasite loads. Using an in vitro assay with immune 
cells from infected mice we have previously shown that macrophage activation in 
response to soluble IgG2a immune complexes, IFN-γ and parasite antigen was 
effective in killing intracellular L. amazonensis. Parasite killing was dependent 
upon FcRγ common-chain and NADPH oxidase-generated superoxide from 
infected macrophages. Here we show that antibody-enhanced intracellular killing 
is associated with an upregulation of autophagy as determined by an increase in 
LC3II and colocalization of LC3 with parasites within parasitophorous vacuoles. 
LC3 colocalization and superoxide production were dependent upon the PKCδ 
pathway. These experiments define a new mechanism by which antibodies can 
promote killing of an intracellular pathogen post-infection. 
 
 
  
54
Introduction 
Leishmaniasis is a vector-borne intracellular protozoan parasite transmitted by 
the bite of a sand fly, which transmits an infectious metacyclic promastigote that 
subsequently transforms to an amastigote within mammalian macrophages. 
Leishmania amazonensis causes cutaneous leishmaniasis in tropical and 
subtropical countries of the Western hemisphere. Leishmania parasites have 
been shown to interfere with host cell functions, including the modulation of 
signaling pathways, suppression of antimicrobial and pro-inflammatory 
mediators, and induction of cytokines that promote disease progression.1 Control 
of L. amazonensis within macrophages in vitro requires the production of reactive 
oxygen species and nitric oxide.2, 3 Currently treatment is through the use of 
pentavalent antimonials.4 Cutaneous and mucocutaneous leishmaniasis 
treatments are often poorly justified due to their limited effectiveness and 
numerous side effects. More research is needed to develop better treatment 
options with less severe side effects and better efficacy. 
Autophagy plays a role in cell survival throughout health and disease 
including, aging, cancer, neurodegenerative diseases, immunity, infectious 
diseases, and chronic inflammatory conditions.5 Canonical autophagy is an 
intracellular homeostatic mechanism important for the degradation of cytosomal 
components that range in size from single proteins to entire organelles via 
autodigestion through the lysosomal pathway. Multiple autophagic pathways 
exist in mammalian species and can be either nonselective or selective. 
Selective autophagy can target intracellular microorganisms in a process known 
  
55
as xenophagy, and multiple host factors and pathways are activated and 
contribute to this process.6 Autophagosomes can be recognized by their 
association with microtubule-associated protein 1 light chain 3 (LC3), which is 
conjugated with phosphotidylethanolamine (PE) to form LC3II. In canonical 
autophagy LC3II facilitates the formation of a double-membrane autophagosome; 
which fuses with a late endosome or lysosome to form the autolysosome.7  
Recent studies have provided evidence for a role of autophagy in host cell 
defenses.8 Autophagy has been shown to play a role in innate immunity and can 
be activated through numerous pattern recognition receptors to participate in the 
elimination of microorganisms. Other studies have also confirmed that autophagy 
can target intracellular parasites and bacteria, including Listeria monocytogenes, 
Salmonella enterica, Francisella tularensis, and Toxoplasma gondii.9, 10, 11, 12, 13, 
14, 15  
Non-canonical autophagy can be used by phagocytes to kill and digest 
pathogens.16 Non-canonical autophagy is described as autophagy that is 
independent of some of the core canonical machinery components, such as the 
initiation factors ULK1 and ULK2.6 Recently, a form of non-canonical autophagy 
has been described that utilizes LC3 recruitment and the fusion of the 
phagosome and lysosome without the formation of a double membrane 
autophagosome.6, 16, 17 This type of non-canonical autophagy has been referred 
to as LC3-associated phagocytosis (LAP) and can be triggered by innate immune 
receptors such as Fc receptors, TLRs, or C-type lectin receptors.16 LAP is similar 
to canonical autophagy with the utilization of Beclin-1 and class III PI3K activity 
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along with the recruitment of LC3 to the phagosome.16 It is preceded by the 
generation of reactive oxygen species (ROS) through nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, which utilizes the protein Rubicon to 
further recruit LC3II to the phagosome membrane and induce LAP.17, 18   
Inflammatory cytokines have also been involved in the activation of 
autophagy. IFN-γ may activate autophagy through immunity-related GTPases 
and through phosphorylation of beclin 1 by death-associated protein kinase 1 
(DAPK1).19 The signaling mechanisms that autophagy uses for the degradation 
of intracellular microorganisms are largely undetermined. More research is 
needed to elucidate the specific signaling pathways; however, it appears that 
lipid second messengers and phosphatidylinositol 3-phosphate (PI3P) are 
required for autophagy.20 Shahnazari et al. have demonstrated that diacylglycerol 
(DAG) can serve as a signal to promote antibacterial autophagy via PKCδ. This 
leads to the activation of autophagy via NADPH oxidase pathways within 
phagocytes.20  
Reactive oxygen species (ROS) are classical antimicrobial effectors, 
which play an important role in immune signaling. ROS produced by NADPH 
oxidase downstream of TLR or Fcγ receptor stimulation in phagocytes can 
activate non-canonical autophagy.5, 18 We have previously shown that ROS are 
required to kill intracellular Leishmania amazonensis.21 Numerous studies have 
shown a connection between ROS and non-canonical autophagy, although these 
signaling pathways are complex and not completely understood.22  
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In this report we show a mechanism for the reduction in Leishmania 
amazonensis infection through the activation of autophagy, as determined by the 
colocalization of LC3 with the parasite after stimulation of macrophages with 
soluble immune complexes, IFN-γ, and Leishmania antigen. Our lab has 
determined the necessary immune factors required for the reduction of L. 
amazonensis by comparing the limited, transient, infections of L. major to the 
chronic infections of L. amazonensis. We found that mice co-infected with both L. 
major and L. amazonensis would heal their infections. Throughout our studies we 
have determined that superoxide and nitric oxide are required to kill L. 
amazonensis. We have also determined that the production of superoxide can be 
achieved through the stimulation of macrophages by soluble immune complexes, 
IFN-γ, and Leishmania antigen.23 We hypothesize that these three immune 
factors are providing receptor cooperation to stimulate non-canonical autophagy 
and removal of the parasite. These results are similar to the findings of 
Bezbradica et al, in which they found receptor cooperation between FcγRI and 
IFN-γR for the induction of the antimicrobial functions.24 We found have found 
that activating macrophages with soluble immune complexes, IFN-γ, and 
Leishmania antigen, we not only see killing of the parasite; but we also find 
upregulation of autophagy which was dependent upon PKCδ. This is also similar 
to other studies that have shown a role of non-canonical autophagy in the 
clearance of intracellular microorganisms and its regulation by PKCδ.9, 10, 11, 12, 13, 
14, 15 
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Materials and Methods 
 
Mice 
C3HeB/FeJ (C3H) mice (8-10 weeks of age) were obtained from an in-house 
breeding colony. Mice were maintained in a specific pathogen-free facility. Bone 
marrow from PKCδ-/- and C57BL/6 (B6) mice were obtained as a gift from Dr. A. 
Kanthasamy. All procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at Iowa State University.  
Bone marrow macrophages and cell culture 
Bone marrow cells were harvested from femurs and tibias of C3H, B6 or PKCδ-/- 
animals (1-3 mice per experiment) and plated in 150 x 15 mm Petri dishes with 
30ml of macrophage growth medium (30% L-cell conditioned medium, 20% fetal 
bovine serum (FBS), 50% Dulbecco’s modification of eagle’s medium (DMEM), 
2mM L-glutamine, 100 U penicillin per ml, 100µg of streptomycin per ml and 1 
mM sodium pyruvate) at 37°C and 5% CO2, after 2 days an additional 20 ml of 
macrophage medium was added.  At day 7, the adherent cell population was 
collected and, after washing with PBS, trypan blue exclusion was used to count 
live cells, which were resuspended in complete tissue culture medium (CTCM; 
DMEM, 2mM L-glutamine, 100 U penicillin, 100µg streptomycin/ml, 25 mM 
HEPES, 0.05 um 2-mercaptoethanol and 10% FBS). 
RAW 264.7 Cells 
RAW 264.7 mouse macrophage cells were maintained in complete tissue culture 
media (CTCM; DMEM, 2mM L-glutamine, 100 U penicillin, 100µg 
streptomycin/ml, 25 mM HEPES, 0.05 um 2-mercaptoethanol and 10% FBS).  
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Parasites and Antigens 
L. amazonensis (MHOM/BR/00/LTB0016) promastigotes were grown in complete 
Grace’s medium (Atlanta Biologicals, Lawrencville, GA) to stationary phase, 
harvested, washed in endotoxin free PBS (Cellgro, Herdon, VA) and prepared to 
a concentration of 1 x 108 parasites/mL. Freeze-thawed (FT) Leishmania major-
antigen was obtained from stationary phase promastigotes as previously 
described.25  
Macrophage infection and treatments 
Bone marrow-derived macrophages (BMM) or RAW cells were infected with 
promastigotes as indicated in the figure legends at 3:1 parasite to cell ratio. In 
indicated experiments L. amazonensis promastigotes were labeled with 
carboxyfluorescein diacetate succinimidyl ester (CFSE). The infected cells were 
incubated on coverslips at 34°C with 5% CO2 in 24 well plates. After 24 hours, 
cells were washed with warm DMEM to remove extracellular parasites and 
brought to a final volume of 0.5 ml with CTCM.   
Activation of infected macrophages using soluble immune complexes 
Mouse IgG2a  isotype (functional grade purified, eBioscience) was either 
unlabeled or labeled with Alexa Fluor (AF) 647 (Invitrogen), depending on 
experiment. Soluble immune complexes (ICs) were formed by combining mouse 
IgG2a and goat anti-mouse IgG F(ab’)2 (AffiniPure F(ab’)2 Fragment, Jackson 
ImmunoResearch) at a 2:1 molar ratio and incubated for 2 hours at 37°C with 5% 
CO2. ICs were centrifuged at 15,000g for 10 minutes and the supernatant was 
collected for use.26 Twenty-four hours following infection with L. amazonensis 
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promastigotes, macrophages were washed with warm DMEM and the media was 
replaced with 0.5 ml of fresh CTCM. Cells were then incubated with these pre-
formed soluble ICs (10 μg/ml), IFN-γ(Peprotech, 5 ng/ml), FT-Ag (50 μg/ml), 
IgG2a (10 μg/ml), or F(ab’)2 (10 μg/ml), or combinations of these, as indicated. 
Cells were then incubated for 12 or 24 hours at 34°C with 5% CO2. At the 
indicated timepoint, cells were harvested on coverslips and fixed with 4% 
paraformaldehyde for 10 minutes. 
Determination of macrophage infection rate 
Following incubation for 24 hours, coverslips were harvested, fixed and stained 
using nonspecific HEMA 3 stain set (Fisher Diagnostics, Middletown, VA).  
Coverslips were mounted onto glass slides and counted via light microscopy at 
100x oil magnification. Three areas of 100 cells each were examined and the 
number of infected macrophages/100 cells was recorded.  
Immunoblot Analysis 
Protein content of all cell extracts was determined via nanodrop (ND-1000, 
Wilmington, Delaware), according to manufacturer’s recommendations, and all 
samples were normalized to 2 mg/ml using distilled water. Samples (20 to 30 μg 
of protein) were heated for 4 minutes at 95°C in 6x SDS loading buffer and 
electrophoresis was performed on a 12% SDS-polyacrylamide electrophoresis 
gel. Gels were electroblotted onto polyvinylidene fluoride membranes, blocked 
with 5% dry milk, and probed with anti-LC3B antibody (ab48394, AbCam) or anti-
Actin antibody (Sigma). Signals were detected with horseradish-peroxidase-
conjugated goat anti-rabbit antibodies (1:10,000) (Sigma) using the SuperSignal 
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West chemiluminescent substrate (Pierce, Rockford, IL) and exposed to 
autoradiography film (Midsci, St. Louis, MO).  
Determination of superoxide 
Production of superoxide was assessed using CellROX (Invitrogen). CellROX 
was added to cell cultures at a final concentration of 5 μM after 24 hours and 
allowed to sit for 30 min (according to manufacturer’s instructions). Coverslips 
were then analyzed via confocal microscopy. Coverslips were viewed by 
sequential scanning confocal microscopy using an Olympus IX81 inverted scope 
(Olympus America Inc., Center Valley, PA). Image J was used to determine the 
colocalization and intensity of signal of CellROX (superoxide) and parasite. 
Briefly, CFSE positive parasites were isolated and the intensity of Alexa Fluor 
647 positive CellROX was measured in the isolated areas. An average of the 
CellROX intensity was measured taken after analysis of 5 images per each 
treatment group in each experiment. 
Immunofluorescence 
Following incubation for the designated times, coverslips with adherent RAWs 
were harvested and fixed with 4% paraformaldehyde in PBS for 10 minutes at 
room temperature and washed three times with PBS. RAWs were permeabilized 
with 1% Saponin in PBS for 30 minutes at room temperature. After incubation, 
coverslips were washed three times with PBS and incubated for 1 hour at room 
temperature with anti-LC3 conjugated antibody at a 1:200 dilution in 1% Saponin 
in PBS. RAWs were counterstained and mounted with Gold antifade 4’6-
Diamidino-2-phenindole (DAPI) according to manufacturer’s instructions (Life 
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Technologies, Grand Island, NY).  Superoxide production was detected through 
the use of CellROX deep red reagent (Alexa Fluor 647) (Life Technologies, 
Grand Island, NY). CellROX was added to the cells for 30 minutes before 
fixation, according to manufacturer’s instructions. Coverslips were viewed by 
sequential scanning confocal microscopy using an Olympus IX81 inverted scope 
(Olympus America Inc., Center Valley, PA).  
Quantitative colocalization analysis was performed by counting LC3 and parasite 
association using Olympus Fluoview version 2.1c software. 150 parasites were 
counted; those that were in contact with an LC3 puncta were considered positive 
for colocalization, considering LC3 puncta that are involved with the 
parasitophorous vacuole may not co-localize with a parasite residing within the 
vacuole. Image J was used to determine the colocalization and intensity of signal 
of CellROX (superoxide) and parasite.  
 
Results 
Bone marrow derived macrophages infected with Leishmania amazonensis and 
treated with tripartite activation upregulate LC3II.  
We have previously shown that BMM infected with Leishmania amazonensis can 
kill intracellular parasites after activation with soluble immune complexes, 
Leishmania antigen, and IFN-γ (tripartite activation)23. We were interested in the 
mechanisms of this model of parasite clearance and hypothesized that the 
autophagy pathway would be upregulated when macrophages are activated to 
kill intracellular parasites. Shanazari et al found the intracellular pathogen 
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(Salmonella Typhimurium) is targeted by autophagy in mammalian cells and 
dependent upon functional NADPH oxidase. Therefore, we wanted to determine 
if autophagy is also targeting intracellular Leishmania parasites in tripartite 
activated cells. We performed a western blot analysis for LC3II in BMM bone 
marrow derived macrophages infected with Leishmania amazonensis and treated 
24 hours later with soluble IC, Leishmania antigen, and IFN-γ or the appropriate 
controls. Lysates were collected at day 4 post-treatment. We showed a 
significant increase in LC3II whenever soluble IC were added to Leishmania 
amazonensis infected macrophages. (Figure 1) 
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Figure 1. Bone marrow derived macrophages infected with Leishmania 
amazonensis (LA) and activated with tripartite activation upregulate LC3II.  
A: Bone marrow derived macrophages were infected with LA promastigotes and 
activated 24 hours later for 4 days. Treatments included soluble immune 
complexes (IC) (10 μg/ml) with IFN- γ (5 ng/ml) and Leishmania antigen (50 
μg/ml); IgG2a (5 μg/ml) with IFN- γ (5 ng/ml) and Leishmania antigen (50 μg/ml); 
F(ab)2 (5 μg/ml) with IFN- γ (5 ng/ml) and Leishmania antigen (50 μg/ml); IC (10 
μg/ml) with IFN- γ (5 ng/ml); and IC (10 μg/ml) with Leishmania antigen (50 
μg/ml) . Lysates were collected and immunofluorescence was completed for 
LC3II and Actin. In bone marrow macrophages there is an upregulation of LC3 in 
LA infected macrophages whenever soluble immune complexes are added. 
Results are densitometry of 5 separate experiments. B: Image from one 
representative experiment. 
 
IC, G, A IgG, G, A Fab, G, A IC, G IC, A Day 4 LA infected 
LC3II 
A 
B 
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RAW 264.7 macrophages infected with Leishmania amazonensis and treated 
with tripartite activation show a decrease in parasite load at 24 hours post 
treatment 
We have previously shown that this tripartite activation system in bone marrow 
derived macrophages after four days of treatment.23 Next, we wanted to study 
this system in vitro in RAW 264.7 macrophages as they are commonly used in 
autophagy studies and it is known that they produce low levels of NOX2-
generated ROS for a short duration compared to bone marrow derived 
macrophages.27, 28 We showed that RAW 264.7 cells had a decrease in parasite 
load at 24 hours post-activation (Figure 2), compared to four days post activation 
in bone marrow derived cells. Confirming that tripartite activation recapitulates 
the results of bone marrow derived macrophages. However, a western blot for 
LC3II in treated RAW 264.7 cell lysates infected with Leishmania amazonensis 
showed no significant increase in LC3II protein expression compared to controls 
(data not shown). 
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Figure 2. RAW 264.7 macrophages infected with Leishmania amazonensis and 
treated with tripartite activation show a decrease in parasite load at 24 hours post 
treatment 
RAW 264.7 macrophages were infected with LA promastigotes for 24 hours then 
treated for 24 hours (as in Figure 1) until coverslips were collected, fixed and 
mounted for counting infected via light microscopy. Three areas of 100 
macrophages were counted under 100X oil immersion and the number of 
macrophages containing intracellular LA was recorded. The results include three 
separate experiments. a = P<0.0001. 
  
Tripartite activation of infected RAW 264.7 cells leads to colocalization of LC3II 
with Leishmania amazonensis 
Due to the lack of upregulation of LC3II in RAW 264.7 cells we focused on the 
distribution of LC3II in infected and activated cells. We hypothesized that the 
location of LC3II was an important readout as to regulation of autophagy during 
parasite killing post-activation. RAW 264.7 cells infected with Leishmania 
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amazonensis and treated with the tripartite activation (soluble immune 
complexes, Leishmania-antigen, and IFN-γ) had a significant increase in parasite 
and LC3II colocalization as compared to the controls (Figure 3). The addition of 
IgG2a or F(ab)2 alone with Leishmania-antigen, and IFN-γ was not enough to see 
colocalization.  
 
 
Figure 3. Tripartite activation of infected RAW 264.7 cells leads to colocalization 
of LC3II with Leishmania amazonensis. 
RAW 264.7 macrophages were infected with LA promastigotes for 24 hours then 
treated for 24 hours as in Figure 1, until coverslips were collected, fixed and 
mounted for confocal microscopy. LC3/LA colocalization was counted using 
Olympus Fluoview version 2.1c software. Colocalization of 150 parasites with 
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LC3 were counted; those that were in contact or overlapping with an LC3 puncta 
were considered positive for colocalization. A. Examples of positive and negative 
colocalization. Top row: negative colocalization; Middle row: positive 
colocalization; Bottom row: Positive colocalization (arrow), others are negative. 
B. There was a significant increase in LC3/LA colocalization in cells treated with 
soluble IC, IFN-γ, and Leishmania antigen. Results include three separate 
experiments. P=<0.001 C. Tripartite activation shows positive parasite and LC3 
colocalization compared to no treatment which shows no parasite and LC3 
colocalization. The results are pooled from two separate experiments in 
duplicate. 
 
Tripartite activation of infected RAW 264.7 cells leads to an increase in the 
intensity of superoxide associated with Leishmania amazonensis 
Our lab has shown in previous work that both superoxide and nitric oxide are 
necessary to kill intracellular Leishmania amazonensis.21 Therefore, we were 
interested in determining if our system was activating superoxide production near 
the intracellular parasites. We used a CellROX analysis to detect superoxide 
production via confocal microscopy. RAW 264.7 cells were infected with CFSE-
labeled Leishmania amazonensis and treated the following day with soluble 
immune complexes, Leishmania-antigen, and IFN-γ or the appropriate controls. 
At 24 hours post-treatment CellROX was added for 30 minutes and the cells 
were fixed and mounted for confocal microscopy. There was a significant 
increase in the intensity of superoxide overlying the parasite when the cells were 
treated with tripartite activation as compared to the controls. Again, this was only 
true when all 3 activation molecules were added to the treatment and it did not 
occur with the addition of IgG2a or F(ab)2 with both Leishmania-antigen, and 
IFN-γ.  
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Figure 4. Tripartite activation of infected RAW 264.7 cells leads to an increase in 
the intensity of superoxide overlying Leishmania amazonensis. 
RAW 264.7 macrophages were infected with LA promastigotes for 24 hours then 
treated for 24 hours until coverslips were collected, fixed and mounted for 
confocal microscopy. Image J was used to determine the colocalization of 
CellROX (superoxide) and parasite. CFSE positive parasites were isolated and 
the intensity of Alexa Fluor 647 positive CellROX was measured in the isolated 
areas. An average of the CellROX intensity was measured after analysis of 5 
images per treatment group in each experiment. There was a significant increase 
B 
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in CellROX intensity overlying LA in cells treated with soluble IC, IFN-γ, and 
Leishmania antigen. Results are a total of two separate experiments. B. Tripartite 
activation showed a dectectable increase in CellROX intensity overlying 
parasites compared to no treatment. 
 
 
Protein kinase C delta (PKC δ) is required for killing of Leishmania amazonensis, 
LC3II and parasite colocalization, and superoxide production 
Shahnazari et al. found that diacyclglycerol can promote autophagy by recruiting 
PKCδ, which can activate autophagy via c-Jun N-terminal kinase (JNK) and 
NADPH oxidase pathways.20 Due to the similarities to Salmonella infection, we 
hypothesized that this signaling pathway was also playing a significant role in our 
system and that inhibiting this pathway would inhibit the activities of the tripartite 
activation. Bone marrow macrophages were derived from PKCδ-/- on a C57BL/6 
background along with macrophages from wild-type C57BL/6 as controls. The 
macrophages were infected with Leishmania amazonensis promastigotes and 24 
hours later treated with tripartite activation. After 4 days of treatment, cells were 
fixed and analyzed either by light microscope for parasite counts or confocal 
microscopy for LC3 and CellROX localization and production, respectively. 
PKCδ-/- macrophages did not have a decrease in parasite load as compared to 
the wild-type C57Bl/6 controls. Additionally, the PKCδ-/- BMM did not show 
colocalization of LC3II and parasites and did not have an increase in superoxide 
production associated with parasites as compared to the wild-type C57Bl/6 
controls. These results demonstrate that this pathway is integral to the autophagy 
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and NADPH pathways in the clearance of Leishmania amazonensis following 
tripartite activation. 
 
 
 
Figure 5. Protein kinase delta C (PKC-δ) deficient (-/-) bone marrow derived 
macrophages are unable to kill intracellular Leishmania amazonensis, do not 
promote LC3II and parasite colocalization, and do not produce superoxide. 
C57Bl/6 wildtype and PKC δ -/- bone marrow derived macrophages were 
infected with LA promastigotes and treated 24 hours later for 4 days as in Figure 
1. A and B. Coverslips were collected, fixed and mounted for counting infected 
macrophages via light microscopy. LC3/LA colocalization was determined using 
Olympus Fluoview version 2.1c as previously described. C. Coverslips were 
collected, fixed and mounted for confocal microscopy. Image J was used to 
determine the colocalization of CellROX (superoxide) and parasite as previously 
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described. Results are a total of two separate experiments in duplicate. D. Wild-
type and PKCδ -/- cells treated with tripartite activation and processed and 
imaged as in A. E. Wild-type PKCδ -/- cells treated with tripartite activation and 
processed as in C.  
 
Discussion 
Our results show that IFN-γ, soluble immune complexes, and Leishmania-
antigen are all required to trigger an antimicrobial response against Leishmania 
amazonensis.  
Only all three immune factors triggered an antimicrobial response with a 
corresponding increase in superoxide production and colocalization of LC3 to the 
parasite. A recent article has described the structural and functional cooperation 
between the IFN-γ and FcγRI receptors; allowing these receptors to act as a 
coincidence detection system eliciting unique gene-expression programs when 
both receptors are engaged.24 Only the activation of both receptors triggered the 
induction of antimicrobial functions against L. amazonensis. This coincidence 
detection system allows a distinct response when both signals are present; 
however, the extent of dependence on signals from other receptors could vary in 
different situations.24 Here we describe the need for cooperation between the 
activation of three potential receptors in order to induce antimicrobial functions 
against L. amazonensis.  
We show that these effector molecules act through the PKCδ pathways to 
activate autophagy via the NADPH oxidase pathway with colocalization of LC3II 
with the parasite. This pathway is consistent with a recent article that has 
described the promotion of autophagy of Salmonella Typhimurium through these 
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pathways.20 This is also similar to the findings by Shahnazari et al. that 
demonstrate a diacylglycerol-dependent signaling pathway in the regulation of 
antibacterial autophagy.29, 30 Shahnazari et al. propose that DAG acts at the 
target organelle to recruit PKCδ, which can activate autophagy via the JNK and 
NADPH oxidase pathways.20 We found that the loss of PKCδ through the use of 
knock out mice resulted in a loss of the antimicrobial actions of the macrophages 
along with a decrease in LC3 colocalization and superoxide production.  
We found that the addition of soluble immune complexes to bone marrow 
derived macrophages lead to an increase in LC3II. We also found that the 
autophagy pathway can play a role in the clearance of Leishmania amazonensis 
in infected macrophages and PKCδ plays an important role in autophagy 
signaling. We have previously shown that soluble ICs can promote parasite 
clearance through the generation of antibody-dependent superoxide 
production.23 The assembly of NADPH oxidase can eventually lead to the 
recruitment of molecules integral to the autophagy pathway and activation of this 
pathway.27 The activation of antibacterial autophagy by NADPH oxidases has 
been described by Huang et al, which can be extrapolated to other intracellular 
pathogens, such as Leishmania.27  
The immunomodulation of these pathways may lead to potential 
therapeutic benefits for treatment of intracellular pathogens, especially 
Leishmania species. The ability to target the microbe to autophagy pathways 
without the use of antimicrobials could be a potential route to decrease 
antimicrobial resistance amongst pathogens. Here we have described how a new 
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mechanism by which antibodies function to clear an infection via NADPH oxidase 
and autophagy pathways.31 Further research is needed to elucidate the specific 
signaling pathways such as to determine specific signals involved in FcγR 
mediated phagocytosis. Specific signaling and receptor cooperation that is 
involved in the upregulation of autophagy for the clearance of Leishmania 
amazonensis also needs to be elucidated. Finally, determining the specific 
molecules that are involved in the anti-Leishmania autophagy pathway will be 
integral in specifying the type of non-canonical autophagy that is occurring and 
the formation of LAPosomes.  
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Abstract 
We have previously shown that macrophage activation in response to soluble 
IgG2a immune complexes, IFN-γ, and parasite antigen was effective in killing 
Leishmania amazonensis; and that intracellular killing of L. amazonensis 
parasites is dependent upon FcRγ common-chain and NADPH oxidase-
generated superoxide from infected macrophages. Here we show that activation 
of a macrophage with a novel recombinant murine IgG2a-Fc construct will result 
in construct trafficking and induce superoxide production. Preliminary studies 
also show killing of L. amazonensis. A recombinant murine IgG2a-Fc construct 
was created by expressing the protein in HEK293F cells. This construct has 
homologous morphology to the Fc portion of IgG2a consisting of the Fc portion of 
a single heavy chain, which naturally forms a dimer with another heavy chain, 
creating a single homodimer of Fc fragment of IgG2a. These experiments define 
a new mechanism by which recombinant constructs can be developed to 
manipulate the immune response to promote killing of an intracellular pathogen, 
post-infection.  
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Introduction 
Cutaneous leishmaniasis can be caused by the intracellular protozoan parasite 
Leishmania amazonensis. Leishmaniasis is endemic in many tropical and 
subtropical countries, and is currently considered a neglected tropical disease. 
Cutaneous leishmaniasis can lead to severe disease that begins as an insect bite 
that gradually enlarges and can become an open sore with occasional 
disfiguration. Spontaneous resolution generally occurs, although the time to 
resolution varies.1 Clearance of L. amazonensis requires the production of 
reactive oxygen species and nitric oxide.2 There are no available vaccines for 
cutaneous leishmaniasis and most treatments have limited effectiveness with 
numerous side effects. 
Our lab has previously shown that reduction of L. amazonensis is 
parasites in vitro can be dependent upon Fragment crystallizable receptor-γ 
(FcRγ) common-chain, nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase generated superoxide, and iNOS generated nitric oxide from infected 
macrophages. We discovered a method of macrophage activation with non-
specific soluble IgG2a immune complexes, IFN-γ, and parasite antigen that were 
effective in killing L. amazonensis. We have previously found that soluble 
immune complexes promoted a NADPH oxidase-dependent leishmanicidal 
response post-infection.3 This is a novel means by which a host can effectively 
use IgG antibodies to effectively enhance killing of intracellular pathogens.     
Here we describe the production of a novel recombinant protein that has 
homology with the Fc portion of murine IgG2a. This protein was designed to 
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replace the use of non-specific soluble immune complexes in our system for 
activating macrophages. The production of recombinant proteins allows for a 
high yield of proteins that can be tagged with GFP or other proteins. These 
proteins can also be labeled with different glycosylation patterns, which can 
affect their affinity for their receptor.4 
Immunoglobulin engagement of antibody Fc receptors, which are found on 
many cell surfaces, can induce a variety of immune functions by regulating 
intracellular signaling. Antibody Fc receptors are named by their ability to bind a 
specific immunoglobulin isotype. FcγRI (CD64) is present on the surface of 
monocytes and macrophages, and bind, with high affinity, the Fc portion of IgG1 
or IgG2a in humans and mice, respectively. The main immune functions of Fc 
receptor engagement are facilitation of phagocytosis, antibody-dependent cell-
mediated cytotoxicity (ADCC), induction of release of inflammatory mediators, 
and regulation of lymphocyte proliferation and differentiation.5 Given their wide 
array of functions in modulating the immune response new and promising 
strategies have unfolded for developing molecules that are able to mimic FcR-Ig 
interaction to exploit immunoregulation.6  
Cell surface expression of FcγRI can be induced by IFNγ. FcγRI in turn can bind 
monomeric IgG2a and take it up via endocytosis in mice.7 Cross-linked receptors 
lead to internalization of the antigen-antibody complex and activation of the cell 
to produce effector functions, such as superoxide production.7 FcγRI signals 
through a common γ chain and activates the proto-oncogene tyrosine protein 
kinase (SRC) family of kinases, spleen tyrosine kinase (SYK), and has been 
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shown to induce superoxide production when bound by large insoluble IC.8 
However, when small soluble immune complexes (ICs) bind the FcγRI, they are 
internalized by endocytic pathways, leading to other functions, such as receptor 
expression, regulation of signal transduction, antigen presentation, endosome 
recycling, and other actions.9 Other studies have shown that these small soluble 
ICs can also induce superoxide production upon cross-linking of the FcγRI.10, 11 
The ability to manipulate these receptors in order to get a timely and localized 
release of inflammatory mediators can be helpful in inducing an effective immune 
response against intracellular pathogens. In this study we have found that the 
production of novel recombinant Fc constructs can bind and activate 
macrophages to kill intracellular Leishmania amazonensis and induce superoxide 
production. 
 
Materials and Methods 
Mice 
C3HeB/FeJ (C3H) mice (8-10 weeks of age) were obtained from an in-house 
breeding colony. Mice were maintained in a specific pathogen free facility. All 
procedures involving animals were approved by the Institutional Animal Care and 
Use Committee at Iowa State University.  
Bone marrow macrophages and cell culture 
Bone marrow cells were harvested from femurs and tibias of C3H mice and 
plated in 150 x 15 mm Petri dishes with 30 ml of macrophage medium (30% L-
cell conditioned medium, 20% fetal bovine serum (FBS), 50% Dulbecco’s 
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modification of eagle’s medium (DMEM), 2 mM L-glutamine, 100 U penicillin per 
ml, 100 μg of streptomycin per ml, and 1 mM sodium pyruvate) at 37o C and 5% 
CO2, after 2 days an additional 20 ml of macrophage medium was added. At day 
7, the adherent cell population was collected and, after washing with PBS, trypan 
blue exclusion was used to count live cells, which were resuspended in complete 
culture medium (CTCM; DMEM, 2 mM L-glutamine, 100 U penicillin, 100 μg 
streptomycin per ml, 25 mM HEPES, 0.05 μm 2-mercaptoethanol, and 10% 
FBS).  
J774 and RAW264.7 Cells 
The RAW264.7 and J774 mouse macrophage cell lines were maintained in 
complete tissue culture media (CTCM; DMEM, 2 mM L-glutamine, 100 U 
penicillin, 100 μg streptomycin per ml, 25 mM HEPES, 0.05 μm 2-
mercaptoethanol, and 10% FBS). 
Parasites and Antigen 
L. amazonensis (MHOM/BR/00/LTB0016) promastigotes were grown in complete 
Grace’s medium (Atlanta Biologicals, Lawrenceville, GA) to stationary phase, 
harvested, washed in endotoxin free PBS (Cellgro, Herdon, VA) and prepared to 
a concentration of 1 x 108 parasites per ml. Freeze-thawed Leishmania major 
antigen was obtained from stationary phase promastigotes as previously 
described.2 
Transfection of HEK293 cells for the production of the recombinant Fc construct 
HEK293 cell cultures are maintained in Medium A and Medium B at 37oC. 
Approximately 1 x 106 cells per ml are incubated with purified pGEn2 vector 
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encoding the target plasmid DNA for 24 hours. After an additional 4-5 days of 
incubation, cells are harvested for protein purification. The protein is purified 
using protein-A sepharose column and analyzed by SDS-PAGE. 
Macrophage infection and treatments 
RAWs were infected with promastigotes as indicated in the figure legends at 3:1 
parasites to cell ratio. In indicated experiments L. amazonensis promastigotes 
were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE). The 
infected cells were incubated on coverslips at 34oC with 5% CO2 in 24 well 
plates. After 24 hours, macrophages were washed with DMEM to remove 
extracellular parasites and brought to a final volume of 0.5 ml with CTCM. 
Activation of infected macrophages using soluble immune complexes or Fc 
construct 
Mouse IgG2a (functional grade purified, eBioscience) was either unlabeled or 
labeled with Alexa Fluor (AF) 647 (Invitrogen). Soluble immune complexes (ICs) 
were formed by combining mouse IgG2a and goat anti-mouse IgG F(ab’)2 
(AffiniPure F(ab’)2 Fragment, Jackson ImmunoResearch) at a 2:1 molar ratio and 
incubated for 2 hours at 37oC with 5% CO2. ICs were centrifuged at 15,000g for 
10 minutes and the supernatant was collected for use.3 Twenty-four hours 
following infection with L. amazonensis promastigotes, macrophages were 
washed with warm DMEM and the media was replaced with 0.5 ml CTCM. Cells 
were then incubated with these pre-formed soluble ICs (10 μg/ml), IFN-γ (5 
ng/ml, Peprotech), FT-Ag (50 μg/ml), IgG2a (10 μg/ml), or F(ab’)2 (10 μg/ml), or 
combinations of these, as indicated. Cells were then incubated for 12 or 24 hours 
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at 34°C with 5% CO2. At the indicated timepoint, cells were harvested on 
coverslips and fixed with 4% paraformaldehyde for 10 minutes. 
Determination of macrophage infection rate 
Following incubation for 24 hours, coverslips were harvested, fixed and stained 
using nonspecific HEMA 3 stain set (Fisher Diagnostics, Middletown, VA).  
Coverslips were mounted onto glass slides and counted via light microscopy at 
100x oil magnification. Three areas of 100 cells each were examined and the 
number of infected macrophages/100 cells was recorded.  
Binding and inhibition of binding 
Fc construct or IgG2a were added to cell cultures for a given amount of time, as 
indicated, then fixed for immunofluorescence with 4% paraformaldehyde for 10 
minutes and washed three times with 1X phosphate buffered saline (PBS). After 
coverslips were washed they were mounted with Gold antifade 4’6-Diamidino-2-
phenindole (DAPI) according to manufacturer’s instructions (Life Technologies, 
Grand Island, NY).   Binding inhibition study was done by adding Fc construct or 
IgG2a for 30 minutes, then macrophages were washed with endotoxin free PBS 
and the opposing molecule was added to the cells for 10 minutes. The cells were 
then fixed and visualized with confocal microscopy as previously described. 
Endocytosis and phagocytosis inhibition 
RAWs were incubated for 1 hour at 37oC with 80 μM Dynasore, 0.2% DMSO, or 
5 μg/ml of Cytochalasin D in DMEM. After 1 hour, Fc-coated bead, Fc construct, 
along with IFN-γ were added to the appropriate wells. Cells were incubated for 0, 
0.5, 1, 2, 4, and 12 hours then fixed with 4% paraformaldehyde and visualized 
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with confocal microscopy.  
Determination of superoxide 
Production of superoxide was assessed using CellROX (Invitrogen). CellROX 
was added to cell cultures after 24 hours and allowed to incubate at 37oC for 30 
min (according to manufacturer’s instructions). Coverslips were then analyzed via 
confocal microscopy. 
Immunofluorescence 
Following incubation for the designated times, coverslips with adherent RAWs 
were harvested and fixed with 4% paraformaldehyde in PBS for 10 minutes at 
room temperature and washed three times with PBS. RAWs were permeabilized 
with 1% Saponin in PBS for 30 minutes at room temperature. After incubation, 
coverslips were washed three times with PBS and counterstained and mounted 
with Gold antifade 4’6-Diamidino-2-phenindole (DAPI) according to 
manufacturer’s instructions (Life Technologies, Grand Island, NY).  Superoxide 
production was detected through the use of CellROX deep red reagent (Life 
Technologies, Grand Island, NY) as described above. Coverslips were viewed by 
sequential scanning confocal microscopy using an Olympus IX81 inverted scope 
(Olympus America Inc., Center Valley, PA). Image J was used to determine the 
colocalization of CellROX (superoxide) and parasite. Briefly, CFSE positive 
parasites were isolated and the intensity of CellROX was measured in these 
isolated areas. An average of the CellROX intensity was measured after analysis 
of 5 images per each treatment group in each experiment.  
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Results 
Murine IgG2a Fc construct developed in HEK293F cells 
In our in vitro disease model, we are able to kill intracellular L. amazonensis by 
activation of macrophages with soluble immune complexes of IgG2a isotype, 
IFN- γ, and Leishmania antigen. We hypothesized that the production of a 
homologous Fc construct protein would act in a similar manner when compared 
to murine IgG2a. Fc construct was produced in HEK293F cells as described in 
materials and methods and purified and tested as a replacement for nonspecific 
soluble IgG2a immune complexes in our previously described tripartite activation 
of macrophages.3 
 
 
Figure 1. Murine IgG2a Fc construct developed in HEK293F cells. The construct 
is tagged with GFP and Avi for biotin binding and naturally forms a dimer.  
 
Fc construct binds to murine macrophages 
Murine macrophages incubated with GFP-tagged Fc construct had similar 
staining pattern compared to macrophages incubated with AF 647 labeled 
murine IgG2a. GFP-Fc construct and AF647-IgG2a can be seen along the cell 
membrane and often within the cytoplasm of the murine macrophages (Figure 2). 
Bone marrow derived macrophages and J774 macrophages had similar results 
with RAWs (data not shown).  
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Figure 2. Murine macrophages incubated with GFP-tagged recombinant IgG2a 
Fc construct or with Alexa Fluor 647 labeled IgG2a. A and B: J774 cells 
incubated with Fc (5 μg/ml) (A) or IgG2a (5 μg/ml) (B) for 1 minute. C and D: 
Murine bone marrow derived macrophages incubated for 30 minutes with Fc (C) 
or IgG2a (D). Nuclei were stained with Dapi. Images are representative of three 
separate experiments in duplicate. 
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Fc construct inhibits binding of IgG2a to murine macrophages 
To test the hypothesis that both the Fc construct and IgG2a were engaging the 
same Fc receptors, we performed an inhibition of binding assay. Macrophages 
incubated with Fc construct blocked the binding of IgG2a to the cells and IgG2a 
blocked the Fc construct from binding to the macrophages (Figure 3). Therefore, 
we concluded that these proteins were both binding to the same Fc receptors. 
 
Figure 3. Recombinant IgG2a Fc construct inhibits binding of AF647 labeled 
IgG2a and vice versa. A: Murine bone marrow derived macrophages were 
incubated for 30 minutes with recombinant IgG2a Fc construct (GFP-tagged) (5 
μg/ml) and incubated for 10 minutes with AF647 labeled IgG2a (5 μg/ml). B: 
Murine bone marrow derived macrophages were incubated for 30 minutes with 
Alexa Fluor 647 labeled IgG2a (5 μg/ml) then washed and incubated for 10 
minutes with recombinant IgG2a Fc construct (GFP-tagged) (5 μg/ml). Nuclei 
were stained with Dapi. Images are representative of three separate experiments 
in duplicate. 
 
 
Fc construct activation of RAW264.7 macrophages kills intracellular L. 
amazonensis post-infection 
Previously we have shown that activation of macrophages with soluble immune 
complexes of the IgG2a isotype, IFN- γ, and Leishmania antigen can kill the 
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intracellular parasite. This occurs through the production of superoxide, which is 
required to kill L. amazonensis.3 We hypothesized that soluble immune 
complexes were activating FcRγI leading to the production of superoxide. Since 
the Fc construct and murine IgG2a have similar morphology and binding 
characteristics, we hypothesized that they would have similar mechanisms of 
action. Macrophages were infected with L. amazonensis promastigotes for 24 
hours, then washed and treated with Fc construct and IFN-γ. The percent-
infected macrophages was significantly decreased in the Fc construct and IFN-γ 
treated cells similar to cells activated with soluble immune complexes, IFN-γ, and 
Leishmania antigen (Figure 4). 
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Figure 4. Recombinant IgG2a Fc construct activation of macrophages kills L. 
amazonensis within infected RAW 264.7 macrophages post-infection. 
Macrophages were infected with L. amazonensis promastigotes for 24 hours 
then cells were washed and treated for 24 hours. Treatments included 
biotinylated Fc-construct (Fc-biotin) (5 μg/ml) with IFN- γ (5 ng/ml), biotinylated 
Fc-construct bound to streptavidin (Fc-biotin-streptavidin) (5 μg/ml) with IFN- γ (5 
ng/ml), Fc-construct (Fc) (5 μg/ml) with IFN-γ (5 ng/ml), soluble immune 
complexes (IC) (10 μg/ml) with IFN-γ (5 ng/ml) (G) and Leishmania antigen (50 
μg/ml (A), no treatment, or streptavidin alone (5 μg/ml). The percent-infected 
macrophages were determined via light microscopy. Results are pooled data 
from 4 separate experiments.  
 
Macrophages incubated with Fc construct upregulate superoxide production 
Since we know that soluble immune complexes upregulate superoxide, we 
wanted to demonstrate that the Fc construct would act in a similar manner.3 We 
have demonstrated that the constructs are able to produce similar activation of 
macrophages to reduce the parasite load, we hypothesized that these Fc 
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constructs are inducing superoxide production in order to kill the intracellular 
parasites, similar to soluble immune complexes. L. amazonensis infected murine 
macrophages incubated with Fc construct increased superoxide production 
compared to untreated L. amazonensis infected cells (Figure 5).  
 
 
 
Figure 5. Fc constructs increase superoxide production. A and B: RAW 264.7 
macrophages infected with L. amazonensis incubated for 24 hours with 
biotinylated recombinant IgG2a Fc construct bound to streptavidin and IFN-γ (A) 
or with streptavidin and IFN-γ (B). C and D: Uninfected RAW 264.7 macrophages 
were incubated for 12 (C) and 24 (D) hours with Fc-construct. Nuclei were 
stained with Dapi. Superoxide was visualized with confocal microscopy utilizing 
CellROX (Life Technologies). 
C D
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Recombinant murine IgG2a Fc construct produced a peak of superoxide 
production at 2 hours post treatment. Biotinylated Fc construct bound to 
streptavidin had a peak of superoxide production at 1 hour post treatment and 
remained elevated compared to other groups at 12 hours post treatment (Figure 
6). These differed from the peak of soluble immune complex superoxide 
production, which occurred at approximately 12 hours post treatment (data not 
shown).  
 
 
Figure 6. Biotinylated recombinant IgG2a Fc activated superoxide production at 
approximately 1 hour post activation in RAW 264.7 macrophages with a greater 
intensity than Fc dimers and Fc coated beads, this remained elevated at 12 
hours post treatment. RAW 264.7 cells were activated with biotinylated 
recombinant IgG2a Fc construct and IFN-γ, Fc-construct and IFN-γ, or Fc-
construct coated beads and IFN-γ. Nuclei were stained with Dapi. Superoxide 
production was measured with confocal microscopy using CellROX (Life 
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Technologies) and pixel intensity was measured with Image J. The data is pooled 
from two separate experiments 
 
Inhibition of endocytosis blocks the uptake of soluble immune complexes and Fc 
construct 
Since the non-specific immune complexes required in our system to activate 
macrophages are small and soluble, we hypothesized that these soluble immune 
complexes and the Fc construct with similar morphology were taken up via 
endocytosis. To test this hypothesis we incubated cells with inhibitors of 
endocytosis or phagocytosis, Dynasore and Cytochalasin D, respectively. 
Preliminary results revealed that Dynasore blocked the uptake of Fc construct 
and soluble immune complexes when visualized with confocal microscopy. 
Cytochalasin D, an inhibitor of phagocytosis, did not block the uptake of Fc 
construct or soluble immune complexes (data not shown).  
 
Discussion 
Here we have described the production of a recombinant murine Fc construct 
with homologous morphology to murine IgG2a Fc. These constructs can be 
produced by the transfection of HEK293F cells and protein purification. This 
allows for larger scale of  production of a purified protein product that can be 
strategically analyzed and manipulated as needed. The ability to develop 
recombinant proteins can have many potential uses in the manipulation of the 
immune response. However, more research is needed to understand the 
molecular mechanisms involved in the activation of these specific intracellular 
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events. The production of such products could lead to the development of new 
therapeutic strategies by targeting receptors that have a known therapeutic 
response or those whose actions are newly being discovered  
Intracellular infections can occur due to numerous chronic infectious 
diseases and their resolution is often complex and requires a robust CD4+ Th1, 
cell-mediated immune response. This type of immune response is characterized 
by the production of IFN-γ and often superoxide. Activating an infected cell to 
undergo a Th1 immune response with the production of IFN-γ and superoxide 
can lead to clearance of the intracellular infection.  
We only saw killing of the parasite with the addition of Fc-constructs rather 
than with biotinylated Fc or streptavidin bound biotinylated Fc. This may be due 
to the fact that these constructs will form soluble multimers, which may lead to 
the clustering of the Fc receptors and the induction of prolonged superoxide 
production. In contrast biotinylation or streptavidin binding of the biotinylated Fc 
may lead to large aggregates and subsequent phagocytosis interfering with 
uptake of these particles by endocytosis and the production of prolonged 
superoxide production. 
In this study we have shown that not only can this recombinant Fc 
construct be produced, but it also has similar functions in activating the 
macrophages as compared to murine IgG2a. The Fc construct can bind to 
murine macrophages in vitro and elicit the activation of the macrophages through 
the production of superoxide and killing intracellular L. amazonensis.  
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CHAPTER 5  
 
GENERAL CONCLUSIONS 
 
Summary 
The work presented in this dissertation demonstrates the ability to activate 
macrophages in vitro with soluble immune complexes, IFN-γ, and Leishmania 
antigen in order to kill intracellular Leishmania amazonensis in an established 
infection. This describes a novel mechanism in which antibodies can be used for 
immune modulation to kill parasites. A major component of the tripartite 
activation is the production of soluble immune complexes. Our findings show the 
importance of a B cell response in this model. In our first studies we attempted to 
knock down B cells for a model of B cell deficient leishmaniasis. However, our 
findings indicated that despite depletion of B cells with anti-CD20 C3H mice are 
still able to resolve cutaneous lesions due to a coinfection with L. major and L. 
amazonensis and an antibody response persisted (or vice versa).  
We were also able to determine important immune factors that were 
involved during the tripartite activation, which led to the clearance of the parasite 
via an upregulation of autophagy, seen as LC3 colocalization. We showed that 
the tripartite activation of macrophages led to a significant increase in superoxide 
production, which we know is an important factor in killing L. amazonensis. This 
upregulation of superoxide is maintained over 12 hours, which is much longer 
than other studies have found with superoxide production. We were also able to 
determine that the activation of superoxide production was related to the 
upregulation of autophagy through the colocalization of LC3 with parasites within 
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parasitophorous vacuoles. It has been previously demonstrated that this tripartite 
activation depended upon activation of the FcRγ (fragment crystallizable) 
common-chain and NADPH (nicotinamide adenine dinucleotide phosphate) 
oxidase-generated superoxide and here we show a requirement for the protein 
kinase C (PKC) δ pathway. We hypothesize that the stimulation of the FcRγ and 
a C-type lectin receptor activate spleen tyrosine kinase (Syk) and proto-
oncogene tyrosine protein kinase (Src) pathways, which lead to NADPH oxidase 
production and the formation of diacylglycerol (DAG) on Leishmania containing 
parasitophorous vacuoles. DAG then recruits PKCδ to the parasitophorous 
vacuole, which can lead to the activation of autophagy. (Figure 1) There are 
three different pathways that lead to the formation of DAG. 1) Phospholipase D 
(PLD) converts phosphatidylcholine (PC) to phosphatidic acid (PA), which is then 
converted to DAG by phosphatidic acid phosphatase (PAP); 2) 
Phosphatidylinositol bisphosphate (PIP2) is converted to DAG by phospholipase 
C (PLC); 3) sphingomyelin synthase (SMS) converts phosphatidylcholine (PC) to 
DAG. We hypothesize that in our system, DAG is formed through the conversion 
of phosphatidic acid to DAG by a phosphatidic acid phosphatase enzyme. This 
would be similar to the antibacterial autophagy pathway shown by Shahnazari et 
al.1  
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Figure 1. Hypothesized signaling pathway for macrophages infected with 
Leishmania amazonensis (LA) and activated with soluble immune complexes, 
IFN-γ, and Leishmania antigen. This pathway leads to the killing of the 
intracellular parasite by signaling through NADPH oxidase and non-canonical 
autophagy pathways, along with a yet unknown c-type lectin receptor (likely 
Dectin-1). phosphatidic acid (PA), phospholipase D (PLD2) See text for other 
abbreviations. 
 
Finally, we demonstrated that a recombinant murine IgG2a Fc construct 
may be able to replace the use of non-specific soluble immune complexes in our 
system. These Fc constructs can be developed in large quantities of a purified 
product or other engineering opportunities, such as different glycosylation 
patterns. These constructs can then be used to manipulate the immune response 
to promote killing of an intracellular pathogen. Our results demonstrated that 
these constructs are likely taken up via endocytosis and can induce the 
macrophages to produce superoxide after being taken up by the FcRγI.   
 
LA
LA
DAG
Syk
PLD2
PKCdPNADPH
oxidase
O2
O2-
LA
Ag
LC3ILC3II
PA
PA
PARubicon
SRC
  
100
 
References 
1. Shahnazari, S., Namolovan, A., Klionsky, D.J. & Brumell, J.H. A role for 
diacylglycerol in antibacterial autophagy. Autophagy 7, 331-333 (2011). 
 
 
Recommendations for future studies 
An important goal for future studies is to elucidate the specific signaling pathways 
that are involved in the tripartite activation of macrophages and the clearance of 
the intracellular parasites. This would include the important receptors required for 
activation of the coincidence receptor system. We currently know that the FcRγ 
common chain and IFN-γ receptor are important in this system but we are 
uncertain as to the 3rd receptor that is required for the tripartite activation. We 
hypothesize that a C-type lectin receptor is the 3rd receptor required and 
determining the specific receptor is an important step in future studies in order to 
be able to use specific targets or to further the development of a therapeutic. 
Numerous studies link the Dectin-1 receptor to the production of superoxide and 
the use of Dectin-1 knockout mice would help to elucidate whether this receptor 
plays an integral role in the tripartite activation and killing of Leishmania.  
While we have determined that the autophagy pathway involved is 
mediated through the PKCδ pathway, it would again be essential to determine 
which other molecules are involved in this autophagy pathway, specifically 
determining how DAG is activated. The use of PLC, SMS, or PAP inhibitors 
would help determine which pathway is leading to the formation of DAG in our 
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system. Appropriate knock out models and cell lines with transfected GFP-LC3 
would also be crucial in determining these pathways. 
Other future studies that could be performed would include testing the tripartite 
activation of macrophages on other intracellular pathogens such as Salmonella, 
Rhodococcus, Brucella, and Mycobacterium, along with many others. The 
activation of macrophages to induce killing of intracellular pathogens could be a 
novel way to decrease infections without the use of antibiotics, which essentially 
could decrease antibiotic use and the development of antibiotic resistance. 
Another important goal of this research would be to determine the 
mechanisms of activation of the Fc constructs and determine why they produce 
different results than the soluble immune complexes in certain circumstances, 
such as superoxide production. It would be important to characterize the 
structure of the Fc constructs and whether or not they are present in dimers or 
larger constructs. Our findings showed that the superoxide production that was 
due to Fc constructs occurred much earlier than the soluble immune complexes. 
The explanation of these differences would require further experiments with 
purified Fc constructs. 
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